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Zusammenfassung 
Strukturelle Grundlagen zur Komplexbildung von humanem IRSp53 mit dem 
translocated intimin receptor Tir enterohämorrhagischer E. coli 
Enterohämorrhagische E. coli (EHEC) adhärieren an ihre Wirtszelle und induzieren lokale 
Aktinpolymerisation durch Translokation der Effektorproteine Tir und EspFU, welche 
intrazellulär mit Proteinen der humanen IRSp53-Familie und N-WASP interagieren. In dieser 
Studie wurde die Komplexstruktur der aminoterminalen Domäne von IRSp53 mit einem Tir-
Peptid gelöst. Es wurde gezeigt, dass zwei parallel orientierte Tir Moleküle an ein IMD-
Homodimer binden. Durch diese Interaktionen vernetzt sich das Bakterium mit der 
Aktinpolymerisationsmaschinerie der Wirtszelle. Die Struktur zeigt eine bislang unbekannte, 
spezifische Peptid-Bindungsstelle auf der Oberfläche von IMD, welche zwischen IRSp53 und 
dem homologen IRTKS konserviert ist. Das Asn-Pro-Tyr (NPY) Motiv des Tir, essentiell für 
die Ausbildung von Pseudopodien-ähnlichen Strukturen, wird hierbei spezifisch von dieser 
Bindungsstelle erkannt. Die Verifizierung der Interaktion erfolgte durch gezielte Mutagenese 
und in vivo Bindungsstudien. Vermutlich nutzt IRSp53 die NPY-Bindungsstelle aber auch für 
weitere bislang unbekannte Interaktionen mit wirtseigenen Proteinen. 
Strukturelle Charakterisierung der Bindung von Amorfrutinen an den 
peroxisome proliferator-activated receptor gamma 
Amorfrutine wurden kürzlich als neue, ungiftige Naturstoffklasse identifiziert, welche eine 
hohe Affinität zum peroxisome proliferator-activated receptor gamma (PPARγ) aufweisen; 
ein nukleärer Rezeptor der an der Regulation des Lipid- und Glukose-Metabolismuses 
beteilig ist. Rosiglitazone, ein PPARγ-Agonist, wird derzeitig zur Behandlung der Typ-II-
Diabetes verwendet. Der Agonist steigert die Insulinsensitivität, führt allerdings auch zu 
Nebenwirkungen wie Gewichtszunahme. Amorfrutine erhöhen ebenfalls die 
Insulinsensitivität, verhindern aber eine übermäßige Fettspeicherung und normalisieren den 
Triglycerid-Metabolismus. Somit sind Amorfrutine eine vielversprechende Alternative zur 
Behandlung oder Prävention von Typ-II-Diabetes oder allgemein dem metabolischen 
Syndrom. In dieser Studie wird die Aktivierung von PPARγ durch die derzeitig wirksamsten 
Amorfrutine, Amorfrutin 1, 2 und B strukturell charakterisiert. Die hochauflösenden Strukturen 
belegen eine, im Gegensatz zu Rosiglitazone, Helix H12 unabhängige Bindung und 
Aktivierung von PPARγ. Der Vergleich mit Kristallstrukturen von PPARγ im Komplex mit 
anderen Liganden ordnet die Amorfrutine der Gruppe der partiellen PPARγ-Agonisten zu. 
Einige partielle PPARγ-Agonisten zeigten bereits in vivo die Eigenschaft, Insulinsensitivität 
zu induzieren ohne Nebenwirkungen wie Adipogenese hervorzurufen. Da Amorfrutine 
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ungiftige Naturstoffe sind, könnten diese nicht nur als alternative Medikation bei Typ-II-
Diabetes ohne Nebenwirkungen dienen, sondern wären auch als Nahrungsergänzungsmittel 
zur Prävention solcher Krankheiten geeignet. 
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Summary 
Structural Basis for Complex Formation between Human IRSp53 and the 
Translocated Intimin Receptor Tir of Enterohaemorrhagic E. coli 
Actin assembly beneath enterohaemorrhagic E. coli (EHEC) attached to its host cell is 
triggered by the intracellular interaction of its translocated effector proteins Tir and EspFU 
with human IRSp53 family proteins and N-WASP. This study reveals the structure of the 
amino-terminal IMD domain of IRSp53 in complex with a peptide derived from the Tir 
sequence, in which the homodimeric IMD domain binds two Tir molecules aligned in parallel. 
This arrangement provides a protein scaffold linking the bacterium to the host cell's actin 
polymerisation machinery. The structure uncovers a novel, specific peptide binding site on 
the surface of the IMD, which is conserved between IRSp53 and its homologue IRTKS. The 
Tir Asn-Pro-Tyr (NPY) motif, which is essential for pedestal formation, is specifically 
recognised by this binding site. The site was confirmed by mutagenesis and in vivo binding 
assays. It is possible that IRSp53 utilises the NPY binding site for additional interactions with 
as yet unknown partners within the host cell. 
Structural Characterisation of Amorfrutins Bound to the Peroxisome 
Proliferator-activated Receptor gamma 
Amorfrutins were recently identified as a non-toxic class of natural products with high affinity 
to the peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor with 
regulatory functions in lipid and glucose metabolism. The PPARγ agonist rosiglitazone is 
currently used in treatment of type II diabetes. It increases insulin sensitivity but has adverse 
effects such as weight gain. Amorfrutins were also shown to increase insulin sensitivity and 
to normalise triglyceride metabolism, but do not enhance undesired fat storage. Amorfrutins 
therefore represent a very promising alternative for treatment or prevention of type II 
diabetes and the metabolic syndrome in general. This study reveals the structural basis of 
PPARγ activation by the currently most promising amorfrutins, amorfrutin 1, 2, and B. In 
contrast to rosiglitazone, the high resolution structures revealed that PPARγ binding and 
activation by amorfrutins are helix H12-independant. Comparison with complex structures of 
PPARγ with other ligands confirmed that the amorfrutins belong to the group of partial 
PPARγ agonists. Few partial agonists, like amorfrutins 1, were already shown to separate 
adverse effects like adipogenesis from the induced insulin sensitivity in vivo. Thus, the 
amorfrutins have not only the potential to work as alternative drugs to treat diseases like type 
II diabetes without the induction of adverse effects. These non-toxic naturally compounds 
may also act as a dietary supplement to prevent these diseases. 
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1 Chapter I  
 
Structural Basis for Complex Formation 
between Human IRSp53 and the Translocated 
Intimin Receptor Tir of Enterohaemorrhagic E. 
coli 
 
 
1.1 Introduction 
1.1.1 Escherichia coli and the pathogenic deputies  
The ubiquitous commensal bacterium E. coli requires only a combination of few mobile 
genetic elements for changing into a highly adapted pathovar, capable of causing a range of 
diseases from gastroenteritis to extraintestinal infections of the urinary tract, bloodstream, 
and central nervous system (Croxen and Finlay, 2010). These genetic elements are called 
pathogenicity islands (PAIs), encoding for an arsenal of virulence factors like toxins, 
colonization factors, and other virulence factors. PAIs are located on plasmids or integrated 
into the bacterial chromosome and are flanked by prophages, transposons, integrases, and 
transposases to facilitate their mobility (Kirsch et al., 2004).  
Annually hundreds of millions of people worldwide suffer from pathogenic E. coli infections, 
rationalizing extensive research to characterise the different pathovars. Eight pathovars have 
been well characterised and can be classified as either diarrhoeagenic or extraintestinal 
(Kaper et al., 2004). The group of diarrhoeagenic E. coli include enterohaemorrhagic E. coli 
(EHEC), enteropathogenic E. coli (EPEC), enterotoxigenic E. coli (ETEC), enteroinvasive E. 
coli (EIEC), enteroaggregative E. coli (EAEC) and diffusely adherent E. coli (DAEC). 
Uropathogenic E. coli (UPEC) and neonatal meningitis E. coli (NMEC) are classified as 
extraintestinal E. coli (Table 1.1-1), causing urinary tract infections and sepsis/meningitis, 
respectively. All these pathovars need to adhere for their pathogenicity to the host cells, 
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which they achieve by characteristic mechanisms of attaching and exploiting the host cells 
(Croxen and Finlay, 2010). Only EIEC invades the host cell for multiplication and 
dissemination (Kaper et al., 2004).  
 
Table 1.1-1: Sites of pathogenic E. coli colonization and classification into diarrhoeagenic and 
extraintestinal E. coli. EHEC: enterohaemorrhagic E. coli, EPEC: enteropathogenic E. coli, ETEC: 
enterotoxigenic E. coli, EIEC: enteroinvasive E. coli, EAEC: enteroaggregative E. coli, DAEC: diffusely 
adherent E. coli, UPEC: uropathogenic E. coli, NMEC: neonatal meningitis E. coli. 
 Diarrhoeagenic E. coli Extraintestinal E. 
coli 
 EHEC EPEC ETEC EIEC EAEC DAEC UPEC NMEC 
Brain        ● 
Bloodstream       ● ● 
Large bowel ●   ● ●    
Small bowel  ● ●  ● ●   
Kidney       ●  
Bladder       ●  
 
1.1.2 Enterohaemorrhagic E. coli (EHEC) and the haemolytic-uremic syndrome 
(HUS) 
Enterohaemorrhagic E. coli (EHEC) are food-born human pathogenic bacteria that cause 
severe bloody diarrhoea. They are capable of triggering the fatal haemolytic uremic 
syndrome (HUS), the main cause of acute renal failure in childhood and adolescence, 
accompanied by low platelet count and destruction of red blood cells. The course of disease 
(Figure 1.1-1) initiates with watery diarrhoea after a mean incubation period of 3 days post 
infection with EHEC, accompanied by cramping abdominal pain (Karch, 2001). During the 
next 2 to 3 days, in most patients watery diarrhoea turns bloody. Most patients recover 
spontaneously within 7 days (Mead and Griffin, 1998). However, about 15% of infected 
patients younger than 10 years develop HUS (Karch, 2001). The incidence of HUS is about 
1.0/100 000 children below 15 years in Germany and Austria, with a mortality of about 3-5% 
(Mead and Griffin, 1998; Zimmerhackl et al., 2002). Up to 40% of HUS patients exhibit long 
term sequelae 10 to 15 years after onset of the disease, such as chronic renal failure that 
leads to a lifetime dependence on dialysis, or other serious complications, such as persisting 
renal hypertension, proteinuria, diabetes mellitus, or neurological disorders (Karch, 2001; 
Mead and Griffin, 1998; Zimmerhackl et al., 2002). HUS is the most severe complication of a 
potentially avoidable food-borne infection, as the bacteria are transmitted through 
contaminated food in most cases.  
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1.1.3 The EHEC serotype O157:H7 account for 90% of all HUS cases 
The EHEC strains of the O157:H7 serotype, so-named because it expresses the 157th 
somatic ‘O’ and the 7th flagellar ‘H’ antigen according to the Kauffmann-White scheme 
(Institut Pasteur, 2007; Orskov and Orskov, 1992), are the best studied EHEC strains, 
because they are clinically the most relevant pathogenic E. coli in Europe, North America, 
and Japan (Nataro and Kaper, 1998). Strains of the O157:H7 serotype were the first strains 
denoted as enterohaemorrhagic E. coli, which are believed to account for over 90% of all 
cases of HUS in industrial countries (Siegler, 1995), rationalising for instance the routinely 
examination of all diarrhoeal stools for E. coli O157 in the UK (Mead and Griffin, 1998). 
 
 
Figure 1.1-1: History of Infection with EHEC O157:H7. 
 
Screening for EHEC O157:H7 infections relies on the inability of this serotype to ferment 
sorbitol rapidly, a phenotype distinct from most other E. coli, which leads to the formation of 
colourless colonies on sorbitol-containing MacConkey agar (Mead and Griffin, 1998). 
However, due to an increasing incidence of a sorbitol-fermenting serotype of EHEC 
O157:H7, as in the outbreak in Southern Germany of 2002 (Robert Koch-Institut, 2003), 
additional detection methods were introduced such as the use of antisera against the O157 
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antigen or assays for Shiga toxins, which are produced by EHEC (O'Brien et al., 1984) but 
for instance not by the related EPEC (see also section 1.1.4). 
The EHEC serotype O157:H7 possesses a highly conserved 92 kb plasmid, which encodes 
for different potential virulence factors. For instance, it encodes for EHEC haemolysin 
(Schmidt et al., 1995) and a type II secretion system (Schmidt et al., 1997). Although the 
plasmid encodes for several proteins which were expressed during the course of HUS, data 
supporting a role in the pathogenic process for each protein are still missing. Other virulence 
factors clearly play essential roles during infection, mainly the prophage encoded Shiga 
toxins that trigger the HUS (see section 1.1.4), but also other PAI encoded virulence factors, 
important for adhesion and dissemination of EHEC (see section 1.1.5.1). 
 
1.1.4 Shiga toxins (Stxs) of EHEC cause HUS manifestation 
Shiga toxins, or verotoxins, are the main virulence factors of EHEC and are the defining 
characteristics of Shiga toxin-producing E. coli (STEC), which were absent for instance in the 
EHEC related EPEC (Hayward et al., 2006). STEC produce two major toxins with a 
sequence identity of 56%, Stx1 and Stx2 (Jackson et al., 1987). Two variants of Stx1 (Stx1 
and Stx1c) as well as several variants of Stx2 (Stx2, Stx2c, Stx2d, Stx2e and Stx2f) are 
known, with a sequence identity of 84-99% of the homologous to Stx2 (Johannes and 
Romer, 2010). The Shiga toxins are prophage encoded multi-subunit protein complexes that 
binds to the glycosphingolipid receptor Gb3 (CD77) on the surface of certain eukaryotic cell 
types, leading, depending on the target cell type, to apoptosis or the induction of an 
inflammatory response (Hayward et al., 2006; Obrig, 2010). During the course of HUS in 
humans, Stx2 and the variant Stx2c are the two mainly produced Shiga toxins (Bockemühl et 
al., 1997). HUS caused by these toxins typically affects the kidney and the gastrointestinal 
tract (Johannes and Romer, 2010).  
 
1.1.4.1 Stxs and their causal role in HUS 
The causal role of Stxs in HUS, summarized by Karch in 2010, has been inferred from: (1) 
Stx production is common to all HUS-associated E. coli isolate regardless of the serotype 
(Karmali et al., 1985); (2) in vivo produced Stxs can be detected in faeces of HUS patients 
(Karmali et al., 1985); (3) HUS patients develop immune responses to Stxs produced by the 
infecting strain (Karmali et al., 1985); (4) intravenous injection of purified Stx causes severe 
disease in laboratory animals, which is prevented by Stx neutralizing antibodies (Richardson 
et al., 1992); (5) in non-immune animals, circulating Stx binds rapidly to the vascular 
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endothelium of target organs (Richardson et al., 1992); and (6) HUS-like disease has been 
described in racing greyhounds orally infected with E. coli O157:H7 (Hertzke et al., 1995) 
and in baboons following injection of purified Stx (Taylor et al., 1999). 
 
1.1.4.2 Stxs are released into the gut by EHEC 
Stx2 and its variant Stx2c seems to be more relevant than Stx1 during the course of HUS 
development and Stx2, in contrast to the almost completely cell associated Stx1, is found in 
the extracellular fraction (Shimizu et al., 2009). Therefore, huge effort has been invested to 
examine especially the mechanism of the Stx2 release into the gut. To date, there are two 
mechanisms suggested to be involved in the release of Stx2 into the gut: (1) a specific 
induction of the Stx2-encoding prophage and (2) a specific Stx2 secretion mechanism 
(Shimizu et al., 2009). 
The release of Stx2 by EHEC into the gut as a result of specific induction of the Stx2-
encoding prophage is mediated by the SOS response, a repair mechanism of bacteria 
induced by DNA damage according to different kind of triggers, like antibiotics or DNase 
colicins (Toshima et al., 2007). The SOS response is regulated by LexA and the 
recombinase A (RecA) and involves the expression of more than 40 genes (Croxen and 
Finlay, 2010). Under normal condition, RecA is transcriptionally repressed by LexA. 
However, DNA damage activates RecA by the interaction with single stranded DNA, 
catalysing the cleavage of its repressor LexA, but also the cleavage of the protein CI, a 
repressor of the lysogenic lambda phage. This leads to an increased production of the 
prophage encoded Shiga toxins, replication of the lambda phage and finally the induction of 
the lambdoid phaged-mediated lysis of the host cell and thus the release of the toxins into 
the gut. Therefore, EHEC infection treatment with antibiotics is often counterproductive as it 
leads to the release of the intracellular toxins and even triggers their expression, as e.g. 
shown for mitomycin C that greatly induce Stx2 expression (Shimizu et al., 2009; Wong et 
al., 2000; Zhang et al., 2000). 
Along with the SOS response-mediated Stxs release by lysis of the host cell, a Stx2 specific 
secretion mechanism is also thought to contribute to the translocation of this toxin into the 
gut (Shimizu et al., 2007; Shimizu et al., 2009). Ser31 of the Stx’s B subunit (see also section 
1.1.4.3) seems to be recognised by a Stx2 secretion system in EHEC, as a S31N mutant 
results in an inhibited extracellular but an increasing cell-associated localisation of Stx2 
(Shimizu et al., 2007; Shimizu et al., 2009). This suggested mechanism causes a 
continuously release of basally expressed Stx2, in contrast to the cell-associated Stx1 
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(Shimizu et al., 2009). However, the detailed mechanism of Stx2 release into the gut remains 
still elusive. 
 
1.1.4.3 Stxs trafficking 
X-ray crystallography revealed a hexameric structure with an AB5 molecular configuration of 
the Shiga toxin, with a molecular mass of 32 kDa of the A and 7.7 kDa of each B subunit, 
respectively (Fraser et al., 1994; Stein et al., 1992). The B subunits, encircling the carboxy-
terminus of the A subunit, dictate the localisation of the Shiga toxins within the bacterial cells 
and thus are responsible for the almost complete cell associated localisation of Stx1 in EHEC 
and the generally extracellular localisation of Stx2 (Shimizu et al., 2007; Weinstein et al., 
1989). Beside its crucial role regarding bacterial localisation, the B subunit also dictates the 
toxins internalization by the host cells. The B subunit exhibit two high affinity and one low 
affinity binding site for three Gb3 molecules, leading to a binding constant in the nanomolar 
range (Bast et al., 1999; Fuchs et al., 1986; Soltyk et al., 2002). The interaction of the B 
subunit with Gb3 on the surface of paneth cells (Schuller et al., 2007), located at the bottom 
of the crypt, induces endocytosis of the toxins. The toxins are then transported in a 
retrograde manner via the golgi to the endoplasmic reticulum (Johannes and Romer, 2010). 
Thereafter the A subunit is activated by an enzymatically cleavage, released into the 
cytoplasm and inactivates the eukaryotic ribosome by the removal of a single adenine base 
from the 28S rRNA within the large 60S ribosomal subunit (Endo et al., 1988). This inhibits 
protein synthesis which may result in apoptosis (Obrig et al., 1988). 
However, it should be noted that Stx is shown to be also present in human Gb3-negative 
intestinal cells, possibly after being taken up by macropinocytosis (Malyukova et al., 2009). 
Macropinocytosis is a non-selective uptake mechanism based on actin cytoskeleton 
rearrangement at the plasma membrane (Lim and Gleeson, 2011), as it occurs during the 
course of EHEC infection (see section 1.1.5.2). However, inside these cells, Stx does not 
prevent protein synthesis or induce apoptosis (Schüller et al., 2004), but may inhibit 
chemokine expression and that in turn would inhibit inflammation (Gobert et al., 2007). 
Furthermore, Stx2 increases the expression of the cell surface protein nucleolin in epithelial 
cells, shown to interact with the cell surface protein intimin of EHEC and thus may contribute 
to the bacterial adhesion (see also section 1.1.5.2) (Robinson et al., 2006; Sinclair and 
O'Brien, 2002). 
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1.1.4.4 Stxs and the fatal consequences in patients 
Stxs provoke local damage of the microcirculation, causing vasculitis, which exacerbates 
mucosal infraction and leads to bleeding into the bowel and thus bloody diarrhoea (Johannes 
and Romer, 2010), the primary clinical symptom of typical diarrhoea-associated HUS. Cattle 
are the main reservoir of STEC, but surprisingly without any clinical symptoms of infection, 
which may be explained by the lack of the Gb3 receptor (Pruimboom-Brees et al., 2000). 
The Stxs are also able to travel by the blood stream to other organs with fatal consequences. 
Peripheral blood monocytes, shown to be Stxs resistant despite their Gb3 receptor, respond 
to Stx interaction with releasing pro-inflammatory cytokines (Harrison et al., 2004; 
Ramegowda and Tesh, 1996) that in turn stimulate Gb3 expression by endothelial cells of 
different organs (Harrison et al., 2004; Johannes and Romer, 2010). Thereby, organs like the 
lung, the central nervous system, but most notably the kidney, were sensitized to Stx 
intoxication. The primary severe damage of the kidney may be explained by its most 
abundant amount of expressed Gb3, but also by the high volume of blood flow and the high 
blood filtration rate and thus a more excessive interaction with the toxin, compared with other 
organs (Obrig, 2010). As mentioned above, the most affected patients are younger than 10 
years which may be ascribed to the fact that only pediatric kidneys express Gb3 in the 
glomeruli (Lingwood, 1994), cells located at the blood-urine barrier. The microenvironment of 
the Gb3 receptor seems to be also critical for the sensitivity of the receptor to the toxins, as 
Gb3 was shown to interact with membrane components like cholesterol, other glycolipids, 
fatty acids, or other proteins (Lingwood et al., 2010a; Lingwood et al., 2010b; Mahfoud et al., 
2010; Nutikka and Lingwood, 2004).  
Furthermore, Stxs trigger a thrombotic mechanism. The toxin induces platelet-leukocyte 
aggregation and expression of tissue factor in the kidney, the brain (Sugatani et al., 2000), 
and blood cells (Stahl et al., 2009). Tissue factor containing microparticles were released, 
enter the circulation and initiate the conversion of fibrinogen to fibrin, resulting in the 
formation of an insoluble fibrin clot (Bach, 1988) and thus increasing the risk of vascular 
congestion. 
Even if Shiga toxins are now commonly accepted as main virulence factors of pathogenic 
STEC (Karch, 2001; O'Brien et al., 1992; Obrig, 2010), their role during the pathogenesis of 
the typical diarrhoea-associated HUS is not yet completely understood. 
 
1.1.4.5 Non-Stx-HUS or atypical-HUS 
The Non-Stx-HUS is less common than the typical Stx mediated and diarrhoea-associated 
HUS, is not diarrhoea-associated, accounts for only 5 to 10% of all cases of the disease and, 
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in contrast to the Stx mediated HUS, may manifest at all ages, but is more frequent in adults 
(Noris and Remuzzi, 2005). As the name already implies, the non-Stx-HUS is not caused by 
Stx, but by non-Stx producing bacteria (Streptococcus pneumonieae), or e.g. by viruses such 
as HIV, different drugs, or systemic diseases like lupus (Noris and Remuzzi, 2005). 
Therefore, this type of HUS is not EHEC mediated and only mentioned in this work for the 
sake of completeness. 
 
1.1.5 The mechanism of EHEC to colonise the human intestine 
After ingestion of the pathogenic bacteria, EHEC have to compete against the bacteria of the 
healthy intestine flora to colonise the gut. To accomplish this task, bacteria take advantage of 
different evolutionary evolved genetic modifications (see section 1.1.5.1), leading to 
expression of different effector proteins that induce host cell’s actin cytoskeleton 
rearrangement and promote their tight adhesion and dissemination. Furthermore, they 
induce diarrhoea, which flushes out less adherent bacteria and thus helps EHEC to colonise 
the intestine (see section 1.1.5.2). 
 
1.1.5.1 The locus of enterocyte effacement (LEE) 
EPEC and most EHEC strains, including EHEC serotype O157:H7, contain almost identical 
copies of the locus of enterocyte effacement (LEE) (Perna et al., 1998). The LEE is a 
chromosomal pathogenicity island that encodes for additional virulence factors aside from 
the prophage encoded Shiga toxins. These factors are essential for EHEC-mediated 
rearrangement of the host cell’s actin cytoskeleton and facilitate adhesion and dissemination 
of the pathogens. The LEE is organized into five major operons, LEE 1 to 5. The LEE, the 
most important PAI, has evolved over the last 4.5 million years (Reid et al., 2000) to a tightly 
packed sequence which contains only the genes of capital importance during the course of 
infection (Kirsch et al., 2004). It comprises 41 open reading frames, encoding transcriptional 
regulators, a type III secretion system (T3SS), chaperones, translocators, the adhesin 
intimin, and effector proteins like the translocated intimin receptor (Tir) (Figure 1.1-2) 
(Garmendia et al., 2005). 
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Figure 1.1-2: Localisation of the major genes involved in EHEC O157:H7 pathogenicity. Shown 
are the locus of enterocyte effacement (LEE), the EspFU and Shiga toxins encoding prophage-U, and 
the plasmid pO157, encoding for proteins like haemolysin (HlyA). The chromosomal pathogenicity 
island LEE of E. coli O157:H7 is shown according to Garmendia et al. (2005). The five putative 
polycistronic operons (LEE1 to LEE5) of EHEC LEE are indicated. EHEC image: Manfred Rohde, HZI. 
 
EPEC as well as EHEC infections lead to so-called attaching-and-effacing (A/E) lesions, 
defined by the attachment of the bacteria to the epithelial cells of the intestinal mucosa and 
the subsequent loss (effacement) of their microvilli. EHEC require the LEE-encoded proteins 
intimin, the corresponding receptor Tir, and EspFU to induce A/E lesion formation in the host 
cell. The prohage-U encoded effector protein EspFU, named according to the similarity to the 
LEE encoded effector protein EspF (Campellone et al., 2004), and Tir need to be 
translocated by the T3SS into the host cell. These three proteins are sufficient to induce A/E 
lesions (see section 1.1.5.2) by a pathway related to EPEC infections (see section 1.1.5.3). 
A/E lesions seem to play a crucial role during EHEC O157:H7 infection. However, LEE is not 
essential for the pathogenesis of all STEC, as some cases of severe disease, including HUS, 
are also caused by LEE-negative STEC strains (Paton et al., 2001). But, these strains are 
thought to use other mechanisms for adhesion, like the LEE-negative O113:H12 STEC 
strain, shown to utilise the adhesin Saa (Paton et al., 2001).  
 
CHAPTER I - INTRODUCTION  22 
1.1.5.2 Attaching-and-effacing (A/E) lesions induce actin pedestal formation 
A/E lesions induced by EHEC lead next to the loss of microvilli to localised actin 
polymerisation and to the formation of pseudopod-like “actin pedestals” beneath the attached 
bacteria (Figure 1.1-2). E. coli typically possess fimbriae, enabling the bacteria to adhere to 
host cells. The Type 1 fimbriae were described first and are the most common adhesins in E. 
coli (Duguid et al., 1955; Welinder-Olsson and Kaijser, 2005) which mediate adherence to 
mannose-containing glycoproteins found on the surface of many eukaryotic cells (Johnson, 
1991). However, the Stx producing EHEC strain O157 is unable to express type 1 fimbriae 
(Enami et al., 1999), but adhere through their common pilus (ECP) (Croxen and Finlay, 
2010) as well as through their type IV pilus, termed haemorrhagic coli pilus (HCP) (Figure 
1.1-3, lower panel) (Xicohtencatl-Cortes et al., 2007). 
Attachment can also be enhanced by interactions of the bacterial outer membrane protein 
intimin with nucleolin, a surface-localised intimin receptor, whose expression is increased by 
Stx2 (see also section 1.1.4.3). The biggest impact on adherence, however, is mediated by 
the interaction of intimin to the effector protein Tir. Tir and a variety of other LEE and phage 
encoded effector proteins are translocated into the host cell via the T3SS (Figure 1.1-3, lower 
panel) (Hayward et al., 2006). Therefore, a deletion of the tir gene results in a profound 
reduction in EHEC colonisation (~10.000-fold), as shown for the infant rabbit intestine 
(Ritchie and Waldor, 2005). Upon secretion, Tir is integrated into the plasma membrane in a 
hairpin-loop conformation and its extracellular domain serves as another receptor for intimin, 
thereby anchoring the bacterium to the host cell (Campellone and Leong, 2003). In this 
arrangement, both termini of Tir project into the host cell cytoplasm providing the recruitment 
sites for the host’s actin polymerisation machinery (Figure 1.1-3). The amino-terminal 
cytoplasmic domain is not strictly required for pedestal formation but modulates pedestal 
length (Campellone et al., 2006). Its exact link to the actin cytoskeleton is still largely unclear. 
In contrast, the carboxy-terminal cytoplasmic domain (TirC) is essential for pedestal 
formation (Campellone et al., 2006). 
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Figure 1.1-3: Schematic representation of A/E lesions during the course of EHEC infection 
according to Croxen et al. (2010) and Weiss et al. (2009), respectively. EHEC adhere to 
colonocytes in the large bowel through the E. coli common pilus (ECP) and the haemorrhagic coli pilus 
(HCP). The EHEC secrete a large arsenal of effector proteins into the host cell by a type III secretion 
system (T3SS). The effector protein Tir integrates into the plasma membrane and serves as a receptor 
for the EHEC cell surface protein intimin. The autoinhibited host protein IRSp53 (or its paralogue 
IRTKS) is activated by interacting with active Cdc42 and is thereby recruited to the membrane. Active 
IRSp53 interacts with Tir and EspFU, another secreted effector protein. EspFU recruits and activates N-
WASP, leading to ARP2/3 dependant actin polymerisation. Thereby, EHEC are linked to the actin 
cytoskeleton of the host cell, resulting in actin pedestal formation. Shiga toxin (Stx) released into the 
gut is internalized, possibly by macropinocytosis, into colonocytes, resulting in inhibition of the innate 
immune response and increased nucleolin expression, which enhances adhesion via additional intimin 
interactions. Stx is internalized into paneth cells via Gb3 receptor-mediated endocytosis. Upon 
enzymatic activation, the toxin prevents protein synthesis of the host cell, which can lead to apoptosis. 
After absorption, Stx can travel with the blood stream to other organs, causing severe damage 
especially to the kidneys. The effector proteins EspG, EspF and Map trigger a disrupted ion balance 
and inhibit water absorption, leading to watery diarrhoea. Inset: Schematic representation of the 
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domain interactions linking TirEHEC to Arp2/3 complex-mediated actin polymerisation during pedestal 
formation. The IMD and SH3 domains of IRSp53 or IRTKS interact with the NPY-motif of TirEHEC and 
the proline-rich repeats of EspFU, respectively. The proline-rich repeats of EspFU are capable of 
interacting with N-WASPs, bound to the Arp2/3 complex which drives actin polymerisation, leading to 
a direct link of the extracellular pathogenic bacterium to the host cell’s actin cytoskeleton. The LEE 
and prophage encoded effector proteins are shown in red and green, respectively. 
 
EspFU, as mentioned before, is also transported via the T3SS into the host cell. EspFU 
comprises a variable number of almost identical, proline-rich 47 amino acid repeats 
(Garmendia et al., 2004; Sallee et al., 2008) (Figure 1.1-3, inset), each including a 
hydrophobic helix that binds to and activates the autoinhibited N-WASP (Campellone et al., 
2004; Cheng et al., 2008), leading to Arp2/3 dependant actin polymerisation. Furthermore, 
the proline-rich repeats are also capable of binding to the Src homology 3 (SH3) domain of 
either the host cell protein IRSp53 (insulin receptor substrate p53) (Weiss et al., 2009) or its 
paralogue IRTKS (insulin receptor tyrosine kinase substrate) (Vingadassalom et al., 2009). 
Due to multiple proline-rich repeats, EspFU was shown to simultaneously bind and activate 
multiple N-WASP proteins (Sallee et al., 2008) and multiple SH3 domains. This allows the 
focal clustering of IRSp53 and Arp2/3 complexes and drives focal actin assembly (Weiss et 
al., 2009), leading to pedestal formation. 
IRSp53 has an SH3 domain, a central Cdc42/Rac interactive binding (CRIB) motif and an 
amino-terminal IRSp53-MIM homology domain (IMD) (see also section 1.1.6.1). The CRIB 
motif seems to be important for the activation of IRSp53, as IRSp53 exists in an autoinhibited 
state in the cytoplasm but becomes activated after the interaction of the CRIB domain with 
the membrane associated active form of Cdc42 (Ahmed et al., 2009). The CRIB domain of 
IRSp53 is atypical, as it comprises less conserved amino acids compared to the typical CRIB 
of e.g. WASP (Krugmann et al., 2001) and thus is also called “partial CRIB”. Despite this, the 
CRIB of IRSp53 binds specifically to active Cdc42 but not to the activated Rac (Krugmann et 
al., 2001; Scita et al., 2008). The activation of the small Rho GTPase Cdc42 is mediated by 
the T3SS secreted effector protein Map (Figure 1.1-3) (Huang et al., 2009). Map was shown 
to induce Cdc42 dependant cell surface filopodia (Kenny et al., 2002) and to work as a 
guanine nucleotide exchange factor (GEF) that specifically activates Cdc42 (Huang et al., 
2009), recruiting the activated IRSp53 to the membrane (Ahmed et al., 2009). Furthermore, 
Map acts as a multifunctional protein that also disrupts the mitochondrial structure and 
function (Ma et al., 2006). 
The IMD of the active IRSp53 interacts with TirC of EHEC, leading to a direct connection of 
the extracellular EHEC with the actin polymerisation machinery of the host cell 
(Vingadassalom et al., 2009; Weiss et al., 2009) and the recruitment of the N-WASP/Arp2/3 
complex to the plasma membrane. The interaction surface within the IMD has been mapped 
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down to a stretch of nine amino acids with a central NPY motif (Campellone et al., 2006). 
Substitutions with alanine demonstrated that each position of the NPY motif but none of the 
neighbouring positions are critical for actin pedestal formation. Interestingly, a conservative 
substitution of the tyrosine by phenylalanine attenuated pedestal formation but could not 
entirely abrogate it (Brady et al., 2007). Despite the related structures of the Tir binding 
proteins IRSp53 and IRTKS, ectopic expression of IRSp53 mediates the formation of 
filopodia (Lim et al., 2008), while cytoskeletal changes induced by IRTKS are more subtle 
(Millard et al., 2005). In any case, these proteins link changes of plasma membrane 
morphology to actin cytoskeleton dynamics (Millard et al., 2005; Scita et al., 2008; Suetsugu 
et al., 2006).  
As mentioned above, along with Tir and EspFU, a lot of other effector proteins are injected 
into the host cell, like Nle (also known as EspI) that reduces protein trafficking and also 
disrupts tight junctions, or the cycle inhibiting factor (Cif) that inhibits the cell cycle 
progression. Some effector proteins account for the primary clinical symptom of an EHEC 
infection, diarrhoea. Diarrhoea provides the EHEC with an advantage over competing flora of 
the intestine, since the intimately bound EHEC remain attached to the host’s intestine and 
other less adherent bacteria are flushed away. The diarrhoea is mediated by the loss of 
absorptive surface due to the loss of microvilli, disrupted ion balance, and water absorption. 
This endothelial dysfunction is triggered by the T3SS translocated effector proteins like EspF 
and EspG, leading to a decreased activity of the Na+/H+ exchanger 3 (NHE3) (Hodges et al., 
2008) and the Cl-/OH- exchanger (Gill et al., 2007), respectively (Figure 1.1-3, lower panel). 
The affected ion absorption leads to diarrhoea, as water moves according to the osmotic 
effect to areas of higher salt concentrations. Furthermore, both proteins induce 
mislocalisation of aquaporin water channels from the membrane into the cytoplasm (Guttman 
et al., 2007). EspF, intimin, Map and Tir also cause the inhibition of the sodium-D-glucose 
co-transporter (SGLT1), a major water pump that accounts for approximately 4 to 6 litre 
water uptake from the intestine per day (Dean et al., 2006; Meinild et al., 1998). The 
inhibition of the intestinal serotonin transporter SERT (Esmaili et al., 2009) and the 
upregulation of connexin 43 (Cx43) (Guttman et al., 2011) were also shown to contribute to 
diarrhoea due to A/E bacterial infection (not shown in the figure). SERT is involved in the 
uptake of serotonin, a hormone regulating fluid and electrolyte secretion and absorption 
(Croxen and Finlay, 2010). Connexin 43 (Cx43) forms open connexon hemichannels in 
apical membranes of infected cells (Guttman et al., 2011). However, up to now no T3SS 
effector proteins are identified to be associated in the SERT inhibition or Cx43 upregulation. 
But these dramatic effects of the secreted virulence factors on the epithelial cells, that also 
include the loss of tight junctions, lead unavoidably to severe diarrhoea. The initially watery 
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diarrhoea turns to bloody diarrhoea within the first weak (Figure 1.1-1), due to the mucosal 
infraction in response to the EHEC produced Shiga toxin (see section 1.1.4.4). 
 
1.1.5.3 Comparison of EHEC and EPEC A/E lesions  
Although EHEC and EPEC are closely related and have an almost identical LEE, EHEC 
injects around twice as many effectors into host cells as EPEC, even if most of these are 
redundant (Tobe et al., 2006). These pathovars exhibit distinct adhesion mechanisms and 
pathways upon attachment that are exploited for inducing actin assembly, as shown for 
EHEC O157:H7 and EPEC O127:H6 or by other, more recently identified EHEC and EPEC 
strains (Frankel and Phillips, 2008). However, there are some correlations in particular 
between the prototypical strains EPEC 1 and the typical non-sorbitol fermenting EHEC O157, 
as shown in Figure 1.1-4 and discussed in the following. Both strains translocate Tir by the 
T3SS into the host. The Tir molecule is well conserved between EPEC, EHEC, and also 
other related bacteria such as Citrobacter rodentium. Only a short stretch of TirC around 
Tyrosine 474 is specific for EPEC-Tir. Phosphorylation of EPEC Y474 by host cell kinases 
(Phillips et al., 2004; Swimm et al., 2004) triggers binding of the SH2-domain of Nck proteins 
(Frese et al., 2006; Gruenheid et al., 2001), resulting in recruitment and activation of N-
WASP and stimulation of Arp2/3 dependant actin polymerisation (reviewed in Hayward et al., 
2006). Thus, in contrast to EHEC, EPEC exploit Nck as part of their infection strategy (Frese 
et al., 2006) and links the bacterium IRSp53 and EspFU independant to the hosts actin 
cytoskeleton.  
 
Figure 1.1-4: Comparison of the signalling cascade of the prototypical strains EHEC O157 (left) 
and EPEC 1 (right). While EHEC require IRSp53 and EspFU to link the bacterium to the host cell’s 
actin cytoskeleton, EPEC exploit Nck as a linker to the actin cytoskeleton, which implicates the 
phosphorylation of Tir’s Tyr474. Figure according to (Croxen and Finlay, 2010). 
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However, even though IRSp53 is present in EPEC but dispensable for EPEC pedestal 
formation, introduction of EspFU into EPEC leads to Nck-independant pedestal formation by 
using an 452NPY454 motif of Tir similar to EHEC Tir (Brady et al., 2007). Thus the canonical 
EPEC is capable of interacting with IRSp53, whereas no information are currently available 
about whether Tyr454 is phosphorylated or not when bound to IRSp53. 
 
1.1.6 The domain organisation of IRSp53 and the homologue proteins IRTKS 
and FLJ22582 
The proteins most closely related to IRSp53 are IRTKS and the poorly characterised 
FLJ22582. These proteins share the two main domains: IMD (see section 1.1.6.1) and SH3 
(see section 1.1.6.2), but also a WASP homology 2 (WH2)-like domain (Figure 1.1-5), 
involved in mediating binding to G-actin (Scita et al., 2008). The partial CRIB domain is a 
unique feature of IRSp53. FLJ22582 lacks also the partial CRIB but in addition the WW 
domain-binding motif (PPPXY). 
 
 
Figure 1.1-5: Domain organization of IRSp53 and the homologue proteins IRTKS and FLJ22582. 
The different domains of the proteins are indicated. 
 
1.1.6.1 The IMD (I-BAR domain) 
The alpha-helical IMDs are distant members of the Bin-Amphiphysin-Rvs (BAR) domain 
superfamily. Whereas canonical banana-shaped BAR domains bind membranes with their 
concave surface and induce invagination, IMDs are cigar-shaped and possess a convex 
surface that interacts with the cell membrane, leading to outward protrusions (Figure 1.1-6) 
like filopodia and are therefore referred to as inverse BAR or I-BAR domains (Frost et al., 
2009; Mattila et al., 2007). Interestingly, IMDs also directly bind to and bundle F-actin 
(Disanza et al., 2006; Millard et al., 2005; Suetsugu et al., 2006). However, two recent 
studies suggested that the isolated IMD itself does not crosslink actin filaments under 
physiological conditions (Lee et al., 2007; Mattila et al., 2007). The actin binding sites 
overlap, at least in part, with those that target lipid membranes (Millard et al., 2005; Suetsugu 
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et al., 2006). IMDs deform PI(4,5)P2-rich membranes (Mattila et al., 2007; Saarikangas et al., 
2009) whereas the IMDs of IRSp53 or IRTKS interact mainly through electrostatic 
interactions with phospholipids of the membrane (Saarikangas et al., 2009). In the resulting 
tubules, the IMDs remain dynamically associated with the inner leaflet and are thought to 
form an inner helical scaffold (Figure 1.1-6B) (Saarikangas et al., 2009). It should be noted 
though, that the basic cluster of amino acids that confers lipid and potentially actin binding to 
IMDs (Millard et al., 2005; Suetsugu et al., 2006) is not required for formation of pedestals by 
EHEC bacteria (Weiss et al., 2009). 
 
 
Figure 1.1-6: Hypothesis of BAR domain mediated membrane curvature. (A) Structural 
comparison of the three different types of BAR domains. Dashed lines indicate the assumed 
membrane binding site. (B) BAR domains lead according to their structure to the formation of 
invaginations (left) or protrusions (right). The BAR domains are hypothesized to exhibit a helical 
scaffold on the cytosolic side of the tubules. Figure (B): (Scita et al., 2008).   
 
1.1.6.2 The SH3 domain 
The SRC homology 3 domain (SH3) plays a critical role in a wide variety of biological 
processes like increasing the local concentration of distinct proteins, altering the subcellular 
localisation of components of signalling pathways or mediating the assembly of large 
multiprotein complexes (Mayer, 2001). SH3 domains interact with proline-rich motifs of 
different proteins. The domain forms a typically β-barrel structure, with anti-parallel β-strands 
that are connected by variable loops. The small interaction surface of about 400Å² results in 
usually weak selectivity and affinities in the low micromolar range to the ligand (Kuriyan and 
Cowburn, 1997). However, affinity and specificity can be greatly enhanced by additional 
contacts between SH3 loop regions and residues of the ligand outside the proline-rich motif 
(Mayer and Saksela, 2004). 
It is not surprisingly that SH3 domains exhibit also a high impact for the IRSp53 signalling, as 
they mediate the interactions to a huge variety of different ligands like WAVE2 (Miki et al., 
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2000), Mena/VASP (Krugmann et al., 2001), Eps8 (Disanza et al., 2006), mDia (Fujiwara et 
al., 2000), espin (Sekerkova et al., 2003), DRLPA (Okamura-Oho et al., 1999), Shank-1 
(Bockmann et al., 2002), and synaptopodin (Yanagida-Asanuma et al., 2007). As the SH3 of 
IRSp53 and IRTKS also interacts with EspFU (Figure 1.1-3), it displays an essential 
component to physically link Tir and thus EHEC to the actin cytoskeleton of the host cell. 
 
1.1.7 Therapeutic treatment of HUS 
The treatment of Shiga toxin-producing bacteria with conventional anti-microbial therapies 
was often reported to be counterproductive since it may stimulate toxin production (Shimizu 
et al., 2009; Wong et al., 2000; Zhang et al., 2000). Due to the worst ever outbreak of the 
very aggressive Stx2 producing HUSECO41 (O104:H4) in Germany 2011, there is a huge 
demand for therapeutic strategies to treat STEC infections and in particular the associated 
HUS. Currently no other therapeutic treatment other than fluid volume control, apheresis and 
dialysis are available to reduce or prevent renal failure. However, there are some promising 
approaches like the synthetic Shiga toxin binder “DAISY” (Mulvey et al., 2003) or “SUPER 
TWIG” (Nishikawa et al., 2002) which acts as a Gb3 analogue neutralizing the toxin. 
Probiotic bacteria with Gb3 mimics on their surface (Paton et al., 2000) or monoclonal 
antibodies against Stx1 and Stx2 were also tested (Mukherjee et al., 2002). Low purity of the 
commercially available Stxs are thought to be the reason for diverging results from related 
experiments, as contaminating substances like lipopolysaccharides are much more potent 
pro-inflammatory agents than Stxs (Obrig, 2010). 
Treatment of HUSECO41 patients with the monoclonal antibody Eculizumab (Soaris; 
Alexion) to prevent the destruction of red blood cells, dramatically demonstrates the need for 
new therapeutic strategies. The antibody is developed to treat paroxysmal nocturnal 
haemoglobinuria, preventing integration of a pore forming terminal complement complex into 
erythrocytes which would cause haemolysis (Parker et al., 2007; Rother et al., 2007). But 
unfortunately so far only limited data is available which describes treatment of human HUS 
patients using this antibody (Gruppo and Rother, 2009; Lapeyraque et al., 2011). 
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1.2 Aim of this work 
IRSp53 and IRTKS were recently discovered to link the human pathogenic bacterium EHEC 
to the host cell actin polymerisation machinery by interactions of their IMD and SH3 domains 
to the translocated effector proteins Tir and EspFU, respectively. 
The aim of this study was to solve the crystal structure of the amino-terminal human IMD of 
IRSp53 in complex with a synthetic peptide derived from the EHEC effector Tir, shown to 
interact with IMD (Weiss et al., 2009). The structure should uncover the unknown binding site 
on the surface of IMD for the NPY motif of the carboxy-terminus of Tir which was already 
proven to be essential for binding (Brady et al., 2007).  
Isothermal titration calorimetry should be used to give information about the thermodynamics 
and the stoichiometry of this interaction. Close inspection of the structure should facilitate 
design of IMD point mutants, predicted to be impaired in Tir binding, to verify the structural 
data. Furthermore, the mutants should identify the most essential residues of the IMD:Tir 
interaction and give information about their impact. 
Hence, this study should reveal a detailed description of a new binding pocket on the surface 
of IRSp53’s IMD, responsible for Tir recognition. The study should unveil how the NPY motif 
provides a central molecular scaffold, linking the bacterium and the host cells actin 
polymerisation machinery. Furthermore, the structure should reveal a novel binding site for 
NPY motifs, which is probably also implicated in interactions with other so far unknown 
interaction partners, effecting pathogenesis and/or actin cytoskeletal regulation. 
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1.3 Materials 
All chemicals were purchased from the following companies: ApliChem, Gold Biotechnology, 
Fluka, Roth, Roche, Hampton Research, Merck, Millipore, Sigma-Aldrich and QIAGEN. The 
quality standard was “pro analysis” (p.a.). 
 
1.3.1 Molecular weight standards 
Precision Plus Protein Unstained Standards and Precision Plus Protein All Blue Standards 
(Biorad) were used for SDS-PAGE analysis. 
 
1.3.2 Media, buffers and stock solutions 
Table 1.3-1: Media, buffer and stock solutions used in this study. 
Media Composition 
Luria Bertani (LB) 10 g/L Bactotryptone, 5 g/l NaCl, 5 g/L yeast extract 
Super broth (SB) 900 ml of solution 1(12 g/L Bactotryptone, 24 g/L yeast 
extract, 0.4% (v/v) glycerol) were mixed with 100 ml of 
solution 2 (0.17 M KH2PO4 and 0.72M K2HPO4). The 
solutions were sterilized separately. 
Buffers Composition 
8x SDS-sample-buffer 7% SDS (w/v), 20% (v/v) glycerol, 0.5 M β-mercapto 
ethanol, 0.25 mg/ml Coomassie Blue G-250, 10 mM 
Tris/HCL pH: 6.8 
SDS-PAGE lower buffer (4x) 1.5 M Tris/HCl pH 8.8 
SDS-PAGE upper buffer (4x) 0.5 M Tris/HCl pH 6.8, 0.4% (w/v) SDS 
SDS-PAGE running buffer 25 mM Tris/HCl, 192 mM glycine, 0.1% (w/v) SDS 
Protease inhibitors Solution 1 (0.88 g PMSF, 10 mg Pepstatin A, 10 mg 
Chymostatin, dissolved in 10 ml DMSO) and solution 2 
(1.57 g Benzamidine, 5 mg Leupeptin, 5 mg Bestatin, 5 
mg Aprotinin, dissolved in 10 ml ddH2O) were sterilized 
by filtration, stored at -20°C and separately added to the 
protein solution in a ratio of 1:1000. 
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1.3.3 Bacterial strains 
Table 1.3-2: Bacterial strains used in this study. 
Bacterial strains Genotype Source 
BL21(DE3) F- ompT hsdSB(rB
-mB
-) gal dcm (DE3) Novagen 
SCS1 recA1 endA1 gyrA96 thi-1 hsdR17(rK
-mK
+) 
supE44 relA1 
Stratagene 
Rosetta2(DE3) F- ompT hsdSB(rB
-mB
-) gal dcm (DE3) pRARE2 
(Cam) 
Novagen 
 
1.3.4 Plasmids for IMD-IRSp53 expression 
pQTEV: A PCR fragment encoding amino acids 1-250 (MSLS…VASN) of human 
IRSp53 (UniProt BAIP2_HUMAN), cloned with BamH1 and NotI into a pQTEV 
(GenBank AY243506), was used for expression, resulting in IMDIRSp53 fused to 
an amino-terminal His7-tag and TEV cleavage site with the sequence 
GSTMSLS…VASN upon cleavage. 
pRARE: The pRARE plasmid (Novagene) encodes tRNA genes to improve the codon 
usage in E. coli of Arg, Ile, Gly, Leu and Pro, except for Arg CCA/CGG (Novy 
et al., 2001). In this study, the pRARE plasmid was used to enhance protein 
expression of IMD-IRSp53 in the SCS1 cells. 
 
1.3.5 IMD constructs 
Table 1.3-3: IMD constructs used in this study. 
Construct  plasmids Bacterial strain 
IMDIRSp53wt 1-250 pQTEV/pRARE SCS1 
IMDIRSp53L28E* as above as above SCS1 
IMDIRSp53K108A* as above as above SCS1 
IMDIRSp53R193S* as above as above SCS1 
IMDIRSp53F196A* as above as above SCS1 
IMDIRSp53K108A/R193S* as above as above Rosetta2 
*The IMD mutants used in this study were kindly provided by Prof. Dr. Theresia Stradal (Institute for 
Molecular Cell Biology, University of Münster, Germany). 
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1.3.6 Peptides 
Table 1.3-4: Peptides used for ITC. 
Peptides Sequenze SwissProt 
EHEC-Tir-peptide 452GTVQNPYADVKT463 Q7DB77 
EHEC-Tir-peptide-Y458F 452GTVQNPFADVKT463 as above 
EPEC-Tir-peptide 448SEVVNPYAEVGG459 B7UM99 
NPxY-peptide of the human 
insulin receptor 
995YSNPEYLSASDV1005 P06213 
 
1.3.7 Crystallisation screens 
Initial crystallisation conditions were identified by using the following screens from QIAGEN: 
JCSG+, JCSG Core I, JCSG Core II, JCSG Core III, JCSG Core IV, The Classics, The 
PEGs, The PEGs II, The MPD, Cryos and The AmSO4. 
 
1.4 Methods 
1.4.1 Production and purification of IRSp53-IMD and IRSp53-IMD mutants 
E. coli SCS1 or Rosetta2 (Table 1.3-3) cells bearing the IMD-IRSp53 expression plasmid and 
pRARE were grown in SB medium supplemented with 100 μg/ml ampicillin and 34 μg/ml 
chloramphenicol at 37°C to an OD of 1.5. Protein expression was induced with 1 mM IPTG at 
37°C for 4 hr. Harvested cells were disrupted with a high pressure cell disrupter (Constant 
Systems) in 20 mM Hepes, pH 7.5, 100 mM NaCl, 10 mM imidazole, 1 mM TCEP and 
protease inhibitors. After centrifugation (35,000×g, 45 min), the soluble protein was purified 
by nickel affinity chromatography (5 ml HiTrap Chelating HP column, GE Healthcare) and 
eluted with an imidazole gradient (10-500 mM) over 20 column volumes. The protein was 
cleavage with his-tagged TEV protease. Uncleaved material and the protease were removed 
by nickel rechromatography, followed by gel filtration (HiLoad 16/60 Superdex 75 prep grade 
column, GE Healthcare) in 20 mM HEPES-NaOH, 100 mM NaCl, 0.1 mM EDTA and 1 mM 
DTT, pH 7.5. The protein purification for isothermal titration calorimetry (section 1.4.3.5) was 
carried out with exception of the His7-tag truncation. 
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1.4.2 IRSp53-IMD:Tir complex formation 
A peptide with the sequence 452GTVQNPYADVKT463, derived from EHEC Tir (see section 
1.3.6), was synthesized and HPLC-purified in-house by Dr. Werner Tegge. The peptide 
contains a carboxy-terminal amide and was used for complex formation and crystallisation 
(see section 1.4.4). The peptide buffer was exchanged against 20 mM HEPES-NaOH, 100 
mM NaCl, 0.1 mM EDTA and 1 mM DTT, pH 7.5. The complex was prepared by adding a 2-
fold molar excess of peptide to purified IMD with a final concentration of 11 mg/ml. 
 
1.4.3 Analytical methods 
1.4.3.1 Photometric quantification of protein concentrations 
The protein concentrations were determined at 280 nm by using a NanoDrop ND-1000 
photometer (peqlab) according to the Lambert-Beer law (Equation 1.4-1), with the extinction 
(E), the intensity of the transmitted beam (I1), the intensity of the incident beam (I0), the 
extinction coefficient (ελ), the protein concentration (c), and the path length (d). The extinction 
coefficients were calculated using the software ProtParam (www.ExPASy.org). 
 
       
  
  
         
Equation 1.4-1 
 
 
 
1.4.3.2 Discontinuous SDS-PAGE 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) was used to analyse protein 
expression and quality (Laemmli, 1970). Protein samples were denatured in 8x SDS sample 
buffer for 5 min at 95 °C and applied next to a molecular standard to an SDS-gel (Table 
1.4-1). The electrophoresis was initially performed at 120 V until the samples were 
concentrated to a thin line in the stacking gel. The electrophoretic separation in the running 
gel was performed at 160 V. The gels were briefly washed in dH2O and subsequently stained 
with InstantBlue (Biozol). 
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Table 1.4-1: SDS gel composition. Specifications according six gels. 
Solutions Running gel Stacking gel 
 12% 5% 
Acrylamide/bisacrylamide 30 % (w/v) 12 ml 1.5 ml 
4x lower buffer 7.6 ml  
4x upper buffer  2.5 ml 
10% SDS 0.3 ml  
H2O 10 ml 5.9 ml 
TEMED 40 µl 30 µl 
25% APS 60 µl 30 µl 
 
1.4.3.3 Dynamic light scattering (DLS) 
Dynamic light scattering (DLS) is a tool to determine size distribution profiles of particles or 
proteins in solution, providing information about the monodispersity or polydispersity and 
thus about complex formation, protein aggregation or degradation. The size distribution 
profile gives also allusion to the crystallisability, whereas proteins with a monodispersity of 
70-80% were shown to have a high probability of producing some kind of crystals (Bergfors, 
1999). DLS determines the scattering intensities of particles exposed to a focused laser 
beam as a function of time. The resulting fluctuation of the intensities, due to the Brownian 
Motion, depend on the particle size. Increasing particle size leads to decreased Brownian 
Motion and increased half-width of the peak maxima. The diffusion constant can be 
calculated by applying an autocorrelation function, leading to the possibility to calculate the 
hydrodynamic radius of the particles, giving information about the size distribution profile of 
particles in the solution. 
For DLS the protein samples with a concentration of 0.5 – 1 mg/ml (leading to approximately 
10% scattering of the laser beam) were filtrated with a 0.2 µm filter to avoid the interference 
of dust. DLS measurements were carried out at room temperature by using a DynaPro Titan 
(Wyatt Technologies) and a laser power of at least 1,000,000 counts/sec. Protein solutions 
with a polydispersity <30% were used for crystallisation. 
 
1.4.3.4 Mass spectroscopy (MS) 
Protein samples from SDS-PAGE were analysed in-house by Dr. Manfred Nimtz and Undine 
Felgenträger using MALDI-TOF-MS. 
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1.4.3.5 Isothermal titration calorimetry (ITC) 
Isothermal titration calorimetry (ITC) is a technique to study biomolecular interactions by the 
direct measurement of protein binding energetics (Leavitt and Freire, 2001). By recording the 
heat of reaction (binding enthalpy, ΔH), directly proportional to complex formation, 
characteristic parameters can be calculated. Numerical approximation to a curve of 
cumulated ΔH (ΔHcum) versus the total ligand concentration (Bt) according to Equation 1.4-2 
facilitates the determination of the enthalpy of formation (ΔHf) and the association constant 
(Ka). The dissociation constant (Kd) corresponds to the reciprocal association constant 
according to Equation 1.4-3. The Gibbs energy changes (ΔG) and entropy changes (ΔS) are 
calculated according to the Van’t Hoff and Gibbs-Helmholtz equation (Equation 1.4-4 and 
Equation 1.4-5). 
 
      
     
      
                                         
     
Equation 1.4-2 
   
 
  
 
Equation 1.4-3 
               Equation 1.4-4 
           Equation 1.4-5 
 
To determine these binding parameters by ITC, a MCS-ITC calorimeter (Microcal, 
Northhampton, MA, USA) was used. Peptides and IMD were dialyzed against 20 mM 
HEPES-NaOH, 100 mM NaCl, 0.1 mM EDTA and 0.8 mM tris(2-carboxyethyl)phosphine 
(TCEP), pH 7.5. During titration, 2 mM peptide was injected into 0.1 mM of His-tagged IMD 
protomers at 24°C in 10 μl steps up to a threefold molar excess. The mixing heat of the 
peptide, measured by injecting peptide into buffer, was subtracted from the signals obtained 
from the binding reactions. ITC data of three independant measurements were analysed 
using Origin V7.0 with Microcal ITC add-on. Peptides 452GTVQNPYADVKT463, derived from 
EHEC Tir, GTVQNPFADVKT, 448SEVVNPYAEVGG459, derived from EPEC Tir (SwissProt 
B7UM99), and a sequence of the human insulin receptor 995YSNPEYLSASDV1005 (SwissProt 
P06213) were synthesized in-house with a caboxy-terminal amide and HPLC-purified by Dr. 
Werner Tegge. 
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1.4.4 Crystallisation by vapour diffusion 
The vapour diffusion technique is the most commonly used method for crystallisation. This 
method based on the presence of a reservoir with precipitant containing mother liquor, 
absorbing water from a crystallisation drop in a closed system. Water vapour diffuses from 
the crystallisation drop, a mixture of protein solution and mother liquor, into the higher 
concentrated reservoir, until equilibrium is reached. The diffusion leads to a gradual 
supersaturation in the crystallisation drop and thus facilitates entropic driven crystallisation 
(Rupp, 2010). 
Prior crystallisation, the concentrated an purified protein of the IRSp53-IMD:Tir complex was 
centrifuged (20 min., 18.000g, 4°C) to separate possible precipitates from the protein 
solution. Crystallisation was performed at 19°C using the vapour phase diffusion method, 
either on a sitting drop for initial screening or on a hanging drop for optimisation. 
 
1.4.4.1 Sitting-drop vapour diffusion 
The sitting-drop vapour phase diffusion method was used for initial screening in 96-well 
format, facilitating the use of robotic systems to mix small amounts of pure protein with 
screen conditions (section 1.3.7).  
200 nl of the purified IMD-IRSp53:Tir protein was mixed with an equal amount of the 
screening conditions in a droplet by using a pipetting robot (Mosquito robot, TTP or 
HoneyBee 961, DIGILAB Genomic Solutions Inc.). The crystallisation was carried out in 3 x 
96 well plates (Greiner), whereas two wells were loaded with different protein concentrations 
(11 mg/ml and 5.5 mg/ml) and the third was loaded with a buffer/precipitant control, to check 
for salt crystal formation. The 96-well plates were sealed using a MancoTM Crystal Clear tape 
(Jena Bioscience) and incubated at 19°C. 
 
1.4.4.2 Hanging-drop vapour diffusion 
The hanging drop vapour phase diffusion method was used for optimisation in a 24-well 
format, by varying the pH, the protein, or precipitant concentration. Protein solution was 
mixed on a cover slip with an equal amount of mother liquor and placed on a well with a 
greased rim upside down over 500 µl of mother liquor. 
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The IMD-IRSp53:Tir complex was crystallised by mixing 2-3 µl of concentrated protein 
(11mg/ml) and 2-3 µl of mother liquor (16% (w/v) PEG 3350, 0.3 M (NH4)2SO4), incubated at 
19°C. 
 
1.4.4.3 Microseeding 
The Seeding technique was used to prevent microcrystal showers and to optimise crystal 
growth and quality. Microcrystal showers are caused or at least favoured by a crystallisation 
setup in a region of high supersaturation and spontaneous nucleation or by an experiment 
that proceeds far into the nucleation zone. This kind of setup often results in the formation of 
many microcrystals, consuming the protein in the crystallisation drop and preventing the 
formation of only a few big crystals. Lowering the concentration may prevent these 
microcrystals, but increase the time for nucleation. Thus it is sometimes worthwhile to identify 
the amount of seeds and the crystallisation conditions, often slightly reduced conditions, to 
optimise crystal quality by microseeding. The strategy of microseeding is to place micro 
seeds, e.g. from a crashed protein crystal, into a low supersaturated protein-precipitant 
solution, where spontaneous nucleation is improbable but nucleation growth of the seeds will 
occur, leading in theory to only a few big crystals. 
5-10 IMD-IRSp53:Tir crystals, resulting from the hanging-drop method, were crushed in 100 
µl of mother liquor (16% (w/v) PEG 3350, 0.3 M (NH4)2SO4) and were diluted ten times 1:10. 
IMD-IRSp53:Tir solution was mixed with an equal amount of each dilution and incubated 
according to the hanging-drop vapour diffusion method. 
 
1.4.5 Data collection, structure determination and refinement 
To prevent or minimise crystal damage by radiation and thermal vibrations, the crystals were 
transferred into reservoir solution with additional 20% (v/v) PEG 400 before flash freezing in 
liquid nitrogen and data collection at 100 K. The data sets were collected at beamline 14.2 of 
the synchrotron storage ring BESSY II in Berlin. Images were indexed and processed with 
the XDS program package (Kabsch, 1993) and the structure was solved by molecular 
replacement using CCP4 MOLREP (Vagin and Teplyakov, 1997) with PDB entry 1Y2O as 
the search model. REFMAC5 (Murshudov et al., 1997) was used for refinement. TLS 
(Translation/libration/screw) (Painter and Merritt, 2006) parameters were included to allow 
domain movements to be refined and Coot (Emsley and Cowtan, 2004) was used for manual 
model building. The validation of the structure was performed using MolProbity (Chen et al., 
2010; Davis et al., 2007). 
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1.4.6 Bioinformatics 
1.4.6.1 Sequence analysis 
Protein sequences were aligned with EMBOSS emma/ClustalW2 (Larkin et al., 2007) and 
displayed with ESPript 2.2 (Gouet et al., 2003). Disordered protein regions were predicted by 
DISOPRED2 (Ward et al., 2004). The proportion of human protein sequences in SwissProt 
containing the NPY motif was determined with Scansite (Obenauer et al., 2003). 
 
1.4.6.2 Structural analysis 
Schematic diagrams of atomic interactions were calculated with LIGPLOT (Wallace et al., 
1995). Buried surface areas were calculated with PISA (Krissinel and Henrick, 2007). Root 
mean square deviations (r.m.s.d.) between common Cα-positions were calculated with ProFit 
using the McLachlan algorithm (McLachlan, 1982).  
 
1.4.6.3 Figure preparation 
Figures were prepared with PyMOL (http://pymol.org), LIGPLOT (Wallace et al., 1995) and 
CorelDRAW X (Corel, Ottawa, Canada).  
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1.5 Results 
1.5.1 Production and purification of IMD-IRSp53 
The IMD of IRSp53 was expressed and purified according to section 1.4.1, using immobilised 
metal ion affinity chromatography (IMAC) for initial purification. Elution of the His7-tag bound 
IMD by a gradient of imidazole, leads already to a high purity of the 31.7 kDa protein due to a 
late elution of the IMD at approximately 450 mM imidazole (Figure 1.5-1). The yield of IMAC 
purified IMD was approximately 40 to 80 mg per litre culture. 
 
 
Figure 1.5-1: IMAC purification of IMD-IRSp53. Bacterial lysate containing the IMD-IRSp53 was 
loaded on a 5 ml HisTrap HP column and eluted with a gradient of 10 to 500 mM imidazole (A). The 
grey and green line depicts the fractions analysed by SDS-PAGE and Coomassie Blue staining (B). 
The fractions marked green were pooled for further purification. M: protein standard. 
 
The His7-tag was truncated from IMD using His6-tagged TEV protease. The truncation avoids 
steric hindrance of crystallisation by the tag and minimises disordered regions, reducing 
unfavourable loss of entropy of the IMD during crystallisation. Nickel rechromatography was 
used to separate the His7-tag and protease from the IMD after cleavage, and gel permeation 
chromatography was used for buffer exchange and final purification. Due to the high purity of 
the protein after the first purification step, the gel filtration column was loaded with the 
maximum of the recommended sample volume of 3% column volume, resulting in an 
expanded protein peak, followed by a second peak which can be attribute to nucleic acids 
(Figure 1.5-2A). SDS-PAGE was used to verify the purity and removal of the ~3 kDa His7-tag 
(Figure 1.5-2B). Prior crystallisation trials, the pooled protein fractions of the gel filtration 
were analysed by MALDI-TOF-MS (section 1.4.3.4) and by DLS (section 1.4.3.3), to ensure 
the identity of the 28.8 kDa IMD and its monodispersity, respectively. 
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Figure 1.5-2: Gel filtration. The IMD elutes at about 62 ml from a Superdex 75 HR 16/60 column (A). 
The peak fraction (50-70 ml) was analysed by SDS-PAGE and Coomassie Blue staining (B), with His7-
tagged IMD protein of the IMAC as a control to verify the successful truncation of the approximately 3 
kDa His7-tag. M: protein standard. 
 
1.5.2 Production and purification of IMD-IRSp53 mutants 
The IMD-IRSp53 mutants used in this study (Table 1.3-3) were expressed and purified 
according to section 1.4.1 with yields and purification profiles during the IMAC and gel 
filtration similar to the wild type IMD (section 1.5.1). SDS-PAGE of purified IMD mutants is 
shown in Figure 1.5-3.  
 
 
Figure 1.5-3: SDS-PAGE of the gel filtration purified His7-tagged IMD mutants. The different 
mutants are indicated. M: protein standard. 
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1.5.3 Crystallisation of the IMD-IRSp53:Tir complex 
Crystallisation trials were performed with either unbound IMD or IMD in complex with an 
EHEC or EPEC Tir derived synthetic dodecapeptide. The complexes were formed according 
to section 1.4.2. Crystallisation conditions were initially screened in 96-well format by using 
the sitting-drop vapour phase diffusion method (section 1.4.4.1). Using the JCSG screens, 
multiple crystallisation conditions for IMD, working as a control, and the IMD in complex with 
either an EHEC or EPEC peptide were identified (Table 1.5-1). However, only the IMD in 
complex with the EHEC derived Tir dodecapeptide could be optimised to well diffracting 
crystals. Even though, crystals appear already after one day using the optimised condition of 
0.3 M ammonium sulphate and 16% PEG 3350 as mother liquor, and microseeding to 
optimise crystal growth, well diffracting crystals needed to grow up to one month at 19°C to 
reach a proper size (Figure 1.5-4) and quality for diffraction up to 2.1 Å (measured at the 
beamline 14.2 of the synchrotron storage ring BESSY II in Berlin). 
 
 
Figure 1.5-4: Optimisation of the crystallisation condition of IMD in complex with the EHEC 
derived Tir dodecapeptide. Initial optimisation of the crystallisation conditions by the hanging-drop 
vapour diffusion technique leads to conjoined needles (A). Further optimisation by using the 
microseeding technique leads to single occurring needles (B). Well diffracting crystal need to grow up 
to one month at the optimised condition and a temperature of 19°C. 
 
1.5.4 Crystal structure of the IMD-IRSp53:Tir complex 
The crystal structure of the complex of the IMD of IRSp53 with a dodecapeptide derived from 
EHEC Tir (GTVQNPYADVKT, residues 452-463) was solved by molecular replacement and 
refined at a resolution of 2.1 Å. The crystallographic data are summarized in Table 1.5-2. 
IMD forms a 170 Å long, cigar-shaped homodimer formed by a bundle of parallel coiled coils 
of kinked α-helices (Figure 1.5-5). The two protomers of the dimer measure about 120 Å in 
length and 30 Å in diameter and bury a surface area of 2,600 Å2. The IMD structure is in 
accord with previously published IMD structures (Lee et al., 2007; Millard et al., 2005; 
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Suetsugu et al., 2006), with a calculated r.m.s. deviation of 0.95 Å to Protein Data Bank 
(PDB) entry 1Y2O (218 common Cα-positions aligned). 
 
Table 1.5-1: Crystallisation conditions for IMD, IMD in complex with an EHEC and EPEC Tir 
derived peptide. Optimised crystallisation condition used for IMD-TirEHEC crystallisation is highlighted 
in blue. 
 Crystallisation conditions Crystal 
form 
IMD  20% (w/v) PEG 3350, 0.2 M lithium nitrate needles 
  20% (w/v) PEG 3350, 0.2 M calcium acetate spheres 
IMD+TirEHEC  0.1 M hepes pH 7.5, 40% (v/v) PEG 400, 0.2 M calcium 
acetate 
spheres 
  0.1 M sodium cacodylate pH 6.5, 40% (v/v) PEG 600, 0.2 M 
calcium acetate 
spheres 
  0.1 M MES, 1.6 M ammonium sulphate, final pH 6.0 spheres 
  0.1M citric acid, 30% (w/v) PEG 6000, final pH 4.0 spheres 
  0.2 M ammonium sulphate, 20% (w/v) PEG 3350 needles 
IMD+TirEPEC  0.1 M sodium cacodylate pH 6.5, 40% (v/v) MPD, 5% (w/v) 
PEG 8000 
spheres 
  0.1 M sodium phosphate-citrate pH 4.2, 40% (w/v) Ethanol, 
5% (w/v) PEG 1000 
needles 
  0.2 M calcium acetate, 0.1 M imidazole pH 8.0, 20% PEG 
1000 
spheres 
  0.2 M lithium sulphate, 0.1 M sodium acetate pH 4.5, 50% 
PEG 400 
spheres 
 
1.5.4.1 Both Tir molecules bound by the IMD point into the same direction 
The electron density map clearly reveals the position of the bound Tir-derived peptide (Figure 
1.5-6A). The IMD homodimer binds two Tir-derived peptides, one at the centre of each 
protomer (Figure 1.5-5). The peptides point into the same direction, almost parallel to the 
two-fold rotation axis of the dimer and perpendicular to the IMD cigar shape. The carboxy-
termini of the peptides point to the site of the IMD that is assumed to face the cytoplasm in 
the membrane bound state. Peptides are located far apart with 91 Å and 61 Å distances 
between their carboxy- and amino-termini, respectively. Each peptide buries 564 Å2 of the 
IMD surface, which is close to the average of buried surface areas in peptide-protein 
interactions (London et al., 2010). The whole length of the Tir-derived peptide is in close 
proximity to the domain, with the two Tir valine side-chains (V454, V461) oriented inwards, 
thus maximising solvent entropy upon binding. All amino acid residues of the peptide and the 
domain are well defined in the electron density map, except for the loop between helices H2 
and H3 and residues 234-250 encoding helix H4.  
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Table 1.5-2: Summary of crystallographic analysis. 
Data collection  
Space group  C2221  
Cell dimensions a, b, c (Å)  88.35, 187.36, 36.81  
X-ray source  Beamline 14.2, BESSY II, Berlin  
Wavelength (Å)  0.9184  
Resolution range (Å)  9.44-2.11  
Last shell (Å)  2.16-2.11  
Rmerge (%)  7.7 (53.2)  
Observations  231684 (9729)  
Unique reflections  18190 (1343)  
Mean (I)/s.d. (I)  20.13 (3.13)  
Completeness  99.8 (100)  
Multiplicity  12.7 (7.2)  
Structure refinement   
  Resolution range (Å)  9.44-2.11 (2.16-2.11)  
  Rwork (%)  23.3   
  Rfree (%)  27.6   
Total number of   
  Non-hydrogen atoms  1991 
  Protein atoms  1837  
  Peptide atoms  103  
  Water molecules  46  
  Sulfate molecules  1  
r.m.s.d.     
  Bond length (Å)  0.022  
  Bond angle (deg)  1.90  
  Main-chain B-factors (Å
2
)  39.4  
  Side-chain B-factors (Å
2
)  43.5  
  Wilson B-factor (Å
2
)  41.8  
  Average B-factor protein atoms (Å
2
)  41.5  
  Average B-factor peptide atoms (Å
2
)  27.0  
  Average B-factor solvent atoms (Å
2
)  40.8  
Ramachandran statistics   
  Most favoured regions (%)  99.1  
  Allowed regions (%)  0.9  
  Disallowed regions (%)  0  
Values in parentheses are for the highest resolution shell.  
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Figure 1.5-5: Complex of IMDIRSp53 with the EHEC Tir-derived peptide. IMDIRSp53 binds a 12-
residue peptide derived from the EHEC virulence factor Tir, incorporating the NPY motif. Ribbon 
diagrams of the two subunits of the IMD homodimer are drawn in cyan and wheat. Two identical 
peptide molecules are coloured blue and yellow, respectively. Peptide amino-termini are labelled with 
an encircled N. 
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1.5.4.2 A novel peptide binding site of IRSp53 recognises the NPY motif 
In the structure of the IMD:Tir complex, the NPY motif of Tir interacts with a large 
hydrophobic binding pocket in the central region of the IMDIRSp53 protomer (Figure 1.5-6A). 
This pocket is also present in the free IMD structure reported by Suetsugu et al. (PDB entry 
1WDZ). On the contrary, in the structure reported by Millard et al. (PDB entry 1Y2O), the 
binding pocket of one of the two protomers is partly occluded by the side-chain of Lys108 
(Figure 1.5-6C,D). The reason for this difference remains unclear. 
All three side-chains of the NPY motif (456-458) are specifically bound by IMDIRSp53. The 
conformation of the peptide backbone is defined by two overlapping type I β-turns (456-459, 
458-461), which are stabilised by three intramolecular hydrogen bonds and an ordered water 
molecule (Figure 1.5-6B, Figure 1.5-7). The pyrrolidine ring of Pro457 of the NPY motif 
further rigidifies the backbone and is accommodated in a shallow hydrophobic groove on the 
IMD surface (Figure 1.5-6A,D).  
The side-chain of Tyr458 of the NPY motif is accommodated in a deep hydrophobic pocket 
and is sandwiched between the hydrophobic portions of the IMD Arg193 and Lys108 side-
chains (Figure 1.5-6A,B). Two ordered water molecules are bound in the interior of the 
pocket and link the Tyr458 hydroxyl group to helices H1, H2, and H3 of IMD (Figure 1.5-7, 
Figure 1.5-6B). Substitution of Tyr458 by phenylalanine would compromise these water-
mediated interactions, which rationalises the reduced pedestal formation of the EHEC-Tir 
Y458F mutant (Brady et al., 2007).  
Recognition of Asn456 of the NPY motif is based on the unique hydrogen bonding potential 
of its side-chain (Figure 1.5-7). The side-chain's carbonyl oxygen is hydrogen bonded to a 
nitrogen of the guanidinium group of IMD Arg193 and accepts an additional, intrapeptide 
hydrogen bond from the backbone nitrogen of Tir Tyr458, an i to i+2 interaction that often 
stabilises Asn-Pro-containing β-turns (Wilson and Finlay, 1997). The side-chain amide 
nitrogen of Asn456 is hydrogen bonded to IMD Glu189. Hydrophobic contacts of the Asn456 
side-chain to Tyr115 further strengthen the interaction. Clearly, asparagine is essential at this 
position, as no other residue could fully satisfy all of the observed bonding constraints.  
Arg193 of IMDIRSp53, part of the signature sequence 
189EERRR193 of the IMD family 
(Yamagishi et al., 2004), appears to be the most critical residue for the recognition of the 
NPY motif. In the free domain, its side-chain is already oriented in the correct conformation 
for binding to Tir Asn456 and Tyr458 by a salt bridge between its guanidinium group and 
Asp112. This is in contrast to Lys108, which has a variable side-chain conformation in the 
absence of the peptide.  
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Figure 1.5-6: Atomic details of the IMDIRSp53:Tir complex. (A) Profile of the binding pocket. The Tir-
derived peptide 
452
GTVQNPYADVKT
463 
is drawn in yellow with its electron density map in blue. 
Dashed lines indicate hydrogen bonds. Tyr458 of the NPY motif is centred by two water molecules 
(red) in the interior of the binding pocket. (B) Stereo view of the interactions of the Tir-derived peptide 
comprising the NPY motif (456-458). Residues involved in the complex interface and in β-turn 
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formation are labelled. The green line represents the backbone of the peptide. Hydrogen bonds 
involved in β-turn formation are shown as red dashed lines. (C and D) Superposition of the free IMD 
structure of Millard et al. (green, PDB 1Y2O) and the peptide-bound IMD (wheat). The side-chain of 
Lys108 blocks the binding pocket in the free structure. The conformation of the side-chain of Lys108 in 
the free IMD structure of Suetsugu et al. is similar to the complex (1WDZ, not shown). 
 
 
Figure 1.5-7: Schematic diagram of atomic interactions. EHEC Tir and the IMD’s binding pocket 
are drawn with black and red labels and bonds, respectively. Cyan spheres represent water and 
dashed lines hydrogen bonds. Hydrophobic interactions are indicated by spoked arcs and atoms with 
spokes. An ordered water molecule and three intra-molecular hydrogen bonds (red) stabilise the 
peptide's two overlapping β-turns. Oxygen atoms are coloured red, nitrogen atoms blue and carbon 
atoms black.  
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In the structure of the free IMD homodimer of Millard et al. (PDB 1Y2O), Arg191 binds to 
Asp232 of the loop linking the opposing protomer's helices H3 and H4 (Figure 1.5-8A). In 
complex to Tir, the Arg191 guanidinium group contacts the oxygens of the peptide's terminal 
carboxylic amide group and of Ala229 of the opposing protomer (Figure 1.5-8B). This 
induced an altered conformation of the loop linking helix H3 and the last helix, H4, which was 
in turn not observed in the structure. These differences may be causative of the entirely 
different crystal packing of the complex (Figure 1.5-8C,D). 
 
 
Figure 1.5-8: Differences in crystal packing of free and peptide loaded IMDIRSp53 facilitates a 
conformational change of H4. (A) In the free structure (PDB 1Y2O), Arg191 of one monomer (green) 
binds to the loop linking helix H3 and helix H4 of the other monomer (orange) and thereby stabilises 
helix H4 adjacent to the dimer. In the structure of the complex (B), the peptide's terminal amide group 
(yellow) binds to the guanidinium group of Arg191 of one IMD monomer (wheat), leading to a 
conformational change of helix H4 and the preceding loop of the other monomer (blue). (C) Crystal 
packing according to Millard et al. of the free IMD (PDB 1Y2O). IMDs are densely packed. The two 
protomers of each dimer are in cyan and wheat, respectively. (D) Crystal packing of the peptide 
loaded IMD displays a more loose array, explaining the undetectability of the loop between H2 and H3 
and of entire H4. Tir peptides are shown in red. Space groups are indicated.  
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1.5.4.3 The Tir binding site is conserved 
The paralogues IRSp53 and IRTKS interact with both EHEC effectors Tir and EspFU via their 
IMD and SH3 domains, respectively. In contrast, the third family member in mammals, 
FLJ22582, only binds EspFU (Weiss et al., 2009). The sequence identity for the IMDs of 
IRSp53 and IRTKS is 47% and all residues contacting the NPY motif are conserved (Figure 
1.5-9).  
 
 
Figure 1.5-9: IMD sequence conservation. Sequence alignment of the known human IMD domains 
of IRSp53, IRTKS, FLJ22582, MIM and ABBA-1 and IRSp53 orthologs from Xenopus tropicalis (claw 
frog), Danio rerio (zebrafish) and Drosophila melanogaster (fruit fly) (GenBank NP_059344, 
NP_061330, NP_079321, NP_055566, NP_612392, NP_001121436, NP_001035335, NP_729679). 
Blue boxes indicate IRSp53 residues in contact to the Tir NPY motif. Red and yellow boxes highlight 
identical and similar residues, respectively. Positions that were mutated in this study are marked by 
asterisks.  
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The IMD of FLJ22582, however, has only a sequence identity of 28% to IRSp53, and the 
residues forming the binding pocket differ markedly. The most prominent difference is 
FLJ22582 Asn108, which replaces Lys108 of IRSp53 (Figure 1.5-10). Lys108 is one of most 
important residues in the binding pocket, stabilising Tyr458 of the NPY motif (Figure 1.5-6B). 
The lack of Tir binding in FLJ22582 may thus be explained by its absence. The Tir binding 
site is highly conserved within the group of IRSp53 and IRTKS orthologues of evolutionary 
distant vertebrates including claw frog and zebrafish, but not in invertebrate orthologues. The 
site is also not conserved in the human IMD proteins MIM and ABBA-1 (Figure 1.5-9). 
 
 
Figure 1.5-10: Mapped IMD sequence conservation. Sequence conservation between the IRSp53 
residues, constituting the hydrophobic binding pocket, and IRTKS (left) or FLJ22582 (right). Deep 
green indicates identity, while purple represents differing residues. 
 
1.5.4.4 ITC analysis to study the effect of mutations on the IMD-IRSp53:Tir 
complex formation 
The complex formation between the IMDIRSp53 and the Tir-derived peptide was studied by 
isothermal titration calorimetry (ITC). The stoichiometry of two peptide molecules per IMD 
homodimer was confirmed, and binding was apparently non-cooperative. A dissociation 
constant of 59 ± 10 µM was determined (Figure 1.5-11), which indicates a weak interaction, 
comparable to SH3-domain interactions with proline-rich motifs (Ball et al., 2005; Kuriyan and 
Cowburn, 1997; Mayer and Saksela, 2004). A corresponding 12-mer peptide was derived 
from EPEC-Tir (SEVVNPYAEVGG) and a similar dissociation constant of 37 ± 14 µM was 
obtained.  
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Binding of the IMDIRSp53 to additional peptides with motifs related to NPY was studied by ITC, 
including the 456NPY458→NPF mutant, described in section 1.3.6, and a peptide derived from 
the insulin receptor comprising the related NPXY motif. No binding was detectable by ITC for 
these NPF and NPXY motif containing peptides (data not shown), demonstrating preference 
of IMD for the NPY motif. To interpret these results, it should be noted that the protein 
concentration used for ITC (100 µM) was close to the dissociation constant of the wild type 
domain and the Tir-derived peptide (60 µM), and it would not have been possible to detect 
binding at lower affinities.  
 
 
Figure 1.5-11: Isothermal titration calorimetry of the binding reaction of IMDIRSp53 and four IMD 
point mutants with peptides derived from EHEC and EPEC Tir, comprising the NPY motif. The 
upper panel shows considerable heat release upon titration of the wild type IMDIRSp53 (black) with the 
EHEC Tir-derived peptide, in contrast to the R193S mutant (red). The heat data, corrected for dilution, 
is plotted against the molar ratio of peptide molecules and IMD protomers in the lower panel. 
Sigmoidal curves typical of exothermic binding reactions were obtained for the wild type IMDIRSp53 and 
the mutant F196A, but not for the R193S, K108A and L28E mutants.  
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Close inspection of the binding site allows the prediction of IMD point mutants, impaired in Tir 
binding without disturbing the overall IMD structure (Figure 1.5-9). These point mutants were 
generated in-house by the group of Theresia Stradal. Substitution of Leu28 by glutamic acid 
(L28E) was predicted to fill the hydrophobic pocket. The residue Lys108 forms a hydrogen 
bond and hydrophobic contacts with the peptide. It is changed to an asparagine in FLJ22582, 
the IRSp53 paralogue that does not recognise Tir. The conformation of the Lys108 side-
chain is stabilised by Phe196. Arg193 may be critically important for recognizing Tir, since it 
is the residue with most interactions with the peptide (Figure 1.5-7) and since the salt bridge 
to Asp112 appears to stabilise the binding pocket. No binding of the Tir-derived peptide was 
detected by ITC when Leu28, Lys108, or Arg193 were substituted in IMDIRSp53 (L28E, K108A, 
R193S in Figure 1.5-11). Binding of the Phe196 point mutant F196A to the peptide was 
weaker than for the wild type domain but still clearly detectable.  
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1.6 Discussion 
1.6.1 The NPY motif of Tir: a ‘hot spot’ for IMD recognition 
The crystal structure presented here reveals the molecular details of the interaction between 
EHEC Tir and the IMD of human IRSp53. It elucidates why the highly conserved NPY motif 
of EHEC Tir is critical for interaction with the IMD of IRSp53 and IRTKS, whereas 
neighbouring residues can be substituted with alanine without any effect (Brady et al., 2007; 
Weiss et al., 2009). The specificity of recognition of Tir by the IMD is determined by the 
characteristic features of the NPY motif's three residues, 456-458. The Asn456 side chain is 
bound by specific hydrogen bonds. The Tyr458 phenyl ring projects into a hydrophobic 
pocket, forming extensive hydrophobic interactions to the IMD, while the phenolic hydroxyl 
group is bound by two water molecules at the bottom of the pocket. Correspondingly, 
substitution of Tyr458 with alanine virtually abolished pedestal formation by EHEC bacteria, 
while substitution with phenylalanine led to a milder defect (Brady et al., 2007). The 
pyrrolidine ring of Pro457 of the NPY motif fits into a shallow hydrophobic cavity on the IMD 
surface. It rigidifies the backbone and supports the formation of two overlapping type I β-
turns in the Tir polypeptide chain.  
The structure described here adds the IMD to the list of known peptide binding domains. The 
binding energy of protein-protein and peptide-protein interactions generally depends on only 
a small number of 'hot spot' residues (London et al., 2010), obviously represented here by 
the NPY motif, including the tightly bound Tyr458. Interestingly, tyrosine ranks on third 
position of the most frequent amino acid residues identified in peptide-protein complexes 
(London et al., 2010). Specific recognition of phosphorylated Tyr474 by Nck proteins is 
essential for pedestal formation by EPEC, as mentioned above. Other tyrosines of EPEC Tir 
at positions 483 and 511 also become phosphorylated and are essential for recruiting SHIP2, 
a host inositol phosphatase controlling pedestal formation by generating a 
phosphatidylinositol 3,4-bisphosphate-enriched lipid platform (Smith et al., 2010). It appears 
that tyrosine-mediated interactions of Tir with specific peptide recognition domains of the 
host cell are critical for pedestal formation of both EHEC and EPEC. 
 
1.6.2 The conserved Tir binding pocket of IMD: the essential residues and 
their relevance for NPY recognition 
The crucial role of certain residues within the IMD NPY binding site revealed by the structure 
was confirmed by site-directed mutagenesis and isothermal titration calorimetry (section 
1.5.4.4). Further binding studies as pull-down assays from lysates and interaction assays in 
living cells, using the Protein Interaction Platform (PIP) assay in yeast (Schmitz et al., 2009), 
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were carried out in cooperation with the group of Prof. Dr. Theresia Stradal (Institute for 
Molecular Cell Biology, University of Münster, Germany), Dr. John M. Leong (Department of 
Molecular Genetics and Microbiology, University of Massachusetts Medical School, 
Worcester, MA, USA) and Cammie F. Lesser (Department of Microbiology and Molecular 
Genetics, Harvard Medical School, Boston, MA, USA), respectively. 
 
Table 1.6-1: IMD mutants used to study the interaction with Tir. ITC and pull-down assays were 
carried out using the IMD of IRSp53, whereas the IMD of IRTKS was used in the PIP assay. The 
sequence of IMDIRTKS aligns the sequence of IMDIRSp53 with a shift of -1. X indicates the use of the 
domain in the corresponding assay. 
IMDIRSp53 IMDIRTKS ITC Pull-down assay PIP assay 
Wt Wt X X X 
L28E L27E X X X 
K108A K107A X X X 
R193S R192S X X X 
F196A F195A X X X 
K108A/R193S K107A/R192S  X X 
 K107A/F195A   X 
R193S/F196A R192S/F195A  X X 
 
The pull-down assays were used to probe the ability of the described IMD mutants (section 
1.5.4.4 and Table 1.6-1) to interact with the Tir-derived peptides or, in contrast to the 
isothermal titration calorimetry, with the entire cytoplasmic carboxy-terminal tail of EPEC- 
and EHEC-Tir (TirC). The pull-down assays were performed from lysates of COS7 cells, 
ectopically expressing the IMD variants as amino-terminal GFP fusions, using biotinylated 
synthetic Tir-derived peptides immobilised on streptavidin-agarose beads as bait. Under 
these conditions, wild type EPEC and EHEC-derived peptides showed significant binding to 
the IMD of IRSp53, and could effectively deplete GFP-tagged IMDs from the lysate and 
enrich in the precipitate (Figure 1.6-1). In contrast, neither the IMD mutants K108A, F196A 
(Figure 1.6-1), nor L28E, R193S, or the IMD double mutants K108A/R193S and 
K108A/F196A (not shown) could be detected in the precipitates. Vice versa experiments 
were performed by using recombinant His-tagged wild type and mutant IMDs as baits in pull-
down assays from lysates of COS7 cells, ectopically expressing the entire TirC. The 
recombinant wild type IMD effectively bound to TirC from both EPEC and EHEC. In 
accordance with the data obtained by ITC, weak but reproducible binding of TirC was also 
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observed for the F196A mutant of IMDIRSp53, while all other IMD mutants were abrogated for 
binding (Figure 1.5-11 and Figure 1.6-1B).  
 
 
Figure 1.6-1: Pull-down assays of Tir with wild type and mutant IMD of IRSp53. (A) Pull-down 
assays of Tir-derived peptides from lysates of mammalian cells ectopically expressing GFP-tagged 
IMD variants of human IRSp53 as indicated on the right. Shown are cell lysates before (load) and after 
(supernatant) pull-downs and precipitates (pull) of three different peptides as indicated above. EHEC 
Tir-derived peptides that bind to Nck instead of IRSp53 (Y474) as well as streptavidin beads were 
employed as bait-control and GFP alone in the cell lysate was the prey-control. (B) Pull-down assays 
of recombinant His-tagged IMD from lysates of COS7 cells ectopically expressing the cytoplasmic 
carboxy-termini of EPEC or EHEC Tir as indicated on the right. Shown is the cell lysate before the 
pull-down (load) and the precipitates (His-IMD pull-down) of wild type IMD (wt) and six variants as 
indicated above. Note the weak binding to mutant F196A in accordance with the ITC measurements.  
 
PIP-assays were used to investigate whether the mutations analysed above within the IMD 
of IRSp53 would also affect the interaction of Tir with IRTKS. Given the strong conservation 
of the Tir binding site, IRSp53 and IRTKS most likely bind to the Tir receptor in the same 
fashion. EHEC TirC and a 456NPY458→AAA substitution mutant (TirC AAA) (Vingadassalom 
et al., 2009) were fused to the scaffolding protein µNS that forms large focal inclusions 
('platforms') in yeast cells. Co-expression of GFP-tagged IMD of IRTKS with the TirC fusion 
protein resulted in complex assembly and formation of fluorescent foci in almost all cells 
(Figure 1.6-2A). The TirC AAA mutant was not able to alter the diffuse intracellular 
localisation of IMDIRTKS, as expected. Substitution of IRTKS Lys107 or Phe195 
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(corresponding to IRSp53 Lys108 and Phe196) partially inhibited the interaction with TirC 
(K107A and F195A, Figure 1.6-2A,B). This was exacerbated by combining both mutations 
(K107A/F195A). Strong inhibition was also observed for the substitution of Leu27 by glutamic 
acid (L27E). Finally, substitution of Arg192 in IRTKS completely abolished the Tir:IMDIRTKS 
interaction (R192S), as the double mutations R192S/F195A and K107A/R192S did (Figure 
1.6-2A,B).  
 
 
Figure 1.6-2: Protein Interaction Platform assay of Tir with wild type and mutant IMD of IRTKS 
in vivo. (A) Yeast cells co-expressing µNS-TirC and wild type or mutant GFP-tagged IMD of IRTKS 
were visualized by fluorescence microscopy 4-5 hours post-induction of fusion protein expression. 
Exemplary GFP inclusions are marked by arrows. The percentage of cells containing GFP inclusions 
was determined visually and is indicated at the bottom right of each image and (B) visualized in the 
histogram. 
 
The interaction of the IMD of IRSp53 and IRTKS with Tir in vitro and in living cells was thus 
impaired by substitution of residues constituting the peptide binding site (Figure 1.5-11, 
Figure 1.6-1 and Figure 1.6-2). The results were conclusive, also concerning residual binding 
that was always found to be strongest for the F196A or F195A mutants, respectively. The 
tight interaction of Arg193 with Tir in the crystal structure was reflected by the complete loss 
of binding upon substitution of the corresponding residues in IRSp53 and IRTKS. 
Substitution of Lys107 or Lys108 in respectively IRTKS or IRSp53 considerably reduced or 
abolished binding. The homologous FLJ22582 has an asparagine at this position, which is 
probably the reason for its lack of binding to Tir (Weiss et al., 2009).  
Full-length IRSp53 was shown to equally well precipitate with both EPEC and EHEC Tir-
derived peptides, containing this NPY motif (Weiss et al., 2009). Moreover, both GFP-tagged 
IRSp53 and endogenous IRSp53 can be readily detected in both EPEC and EHEC pedestals 
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(Weiss et al., 2009). However, in contrast to EHEC, that essentially require IRSp53, it is 
dispensable for EPEC pedestal formation as exemplified by using IRSp53 knockout cells 
(Weiss et al., 2009). Notwithstanding this, introduction of EspFU into EPEC drastically 
increases Nck-independant pedestal formation (Brady et al., 2007). Thus, IRSp53 effectively 
binds to EPEC Tir but no information is available to date on the state of EPEC Tir Y454 
phosphorylation, when bound to IRSp53.  
In Summary, our current data confirm a virtually complete conservation of the binding 
characteristics between IRSp53 and IRTKS to the carboxy-termini of EPEC and EHEC Tir.  
 
1.6.3 The conserved Tir binding pocket of IMD and the preference for NPY 
motifs 
The mode of binding of the NPY motif is strikingly similar to the recognition of NPXY and 
NPF motifs by phosphotyrosine binding (PTB) and Eps15 homology (EH) domains, 
respectively. The NPXY and NPF motifs also form stabilised Asn-Pro type I β-turns, their 
asparagine side-chains are specifically hydrogen bonded and their aromatic side chains 
enter hydrophobic pockets in the respective domains (de Beer et al., 2000; Eck et al., 1996). 
Binding of peptides containing an NPXY or NPF motif by IMD was not detected by ITC, 
indicating preference for NPY over related motifs. 
 
1.6.4 Tir is the first unambiguously IMD binder 
The striking specificity of the recognition of the NPY motif by the IMD suggests that the 
domain has evolved to recognise this motif, a feature that just becomes usurped by 
pathogenic E. coli. Thus it is tempting to speculate that this binding site may have cellular 
ligands that harbour NPY motifs, which occur in up to 3% of human proteins. However, up 
until now, no binding partners for the IMD domains of IRSp53 and IRTKS other than Tir have 
been pinned down unambiguously because the in vivo relevance of its binding to both Rac1 
(Disanza et al., 2006; Krugmann et al., 2001; Miki et al., 2000) and actin (Mattila et al., 2007; 
Millard et al., 2005) is still the subject of debate. 
 
1.6.5 The affinity of Tir 
The almost parallel orientation and the distance of the two Tir-derived peptides in the 
complex suggest that one IRSp53 homodimer can link two Tir molecules in vivo. An affinity of 
CHAPTER I - DISCUSSION  59 
60 µM was found for the binding reaction under in vitro conditions, which is comparable to 
the relatively weak interactions between SH3-domains and proline-rich motifs (Ball et al., 
2005; Kuriyan and Cowburn, 1997). However, the affinity and specificity of ligand binding by 
SH3 can be greatly enhanced by additional contacts between the SH3 loop regions and 
residues of the ligand outside the proline-rich motif (Arold et al., 1998; Mayer and Saksela, 
2004). This is greatly illustrated by the SH3 blocker of Kardinal and colleagues, optimizing a 
high affinity SH3 blocker peptide with a KD in the nanomolar range that competes for the SH3 
of CRKL with Bcr-Abl and hence reduces the proliferation of primary blast cells from chronic 
myeloid leukemia patients (Kardinal et al., 2000). Thus, regions outside the Tir-derived 
peptide might likewise contribute to the binding to IRSp53. This notion is supported by the 
fact that weak binding of the IMD mutant F196A to a longer carboxy-terminal Tir fragment 
was observed in pull down experiments (Figure 1.6-1B), while binding to short Tir-derived 
peptides was not detectable (Figure 1.6-1A). Furthermore, Tir forms homodimers and is 
clustered beneath the attached bacteria upon interaction with intimin (Luo et al., 2000; 
Thierry et al., 2004). Together with the presence of two binding sites on the IMD homodimer, 
this is expected to lead to a higher apparent affinity due to the avidity effect and, 
consequently, efficient recruitment of IRSp53 at physiological concentrations.  
 
1.6.6  Model of the intimin:Tir:IRSp53 complex 
The EHEC bacterium utilises a large protein scaffold including bacterial and host proteins 
that immobilises the bacterium and leads to N-WASP mediated Arp2/3-complex dependant 
actin polymerisation (Weiss et al., 2009). Figure 1.6-3 shows a model of this scaffold 
consisting of Tir, intimin and IRSp53. An alternative model with one IRSp53 homodimer 
linking two distinct Tir homodimers appears also possible. IMDs recognise and even induce 
convex deformation of lipid membranes (Scita et al., 2008; Suetsugu et al., 2006). Membrane 
binding by human IRSp53 is short-lived and highly dynamic (Saarikangas et al., 2009) and it 
is dispensable for pedestal formation (Weiss et al., 2009). The orientation of the Tir-derived 
peptides on the IMD suggest that the flat IMD surface, which is assumed to contact the 
plasma membrane, is oriented towards the membrane in the complex, thus supporting the 
possibility of Tir-bound IRSp53 contacting the plasma membrane. 
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Figure 1.6-3: Model of the intimin:Tir:IRSp53 complex. A model of the scaffold formed by EHEC 
Tir, intimin, and human IRSp53 was drawn to scale based on the available structures. Whether the Tir-
bound IMD interacts with the plasma membrane directly is currently unknown. The extracellular Tir 
and intimin domains are represented by the structure of the complex of the homologues EPEC 
proteins by Luo et al. (PDB entry 1FO2). The model excludes the amino-terminus of Tir, which 
modulates pedestal length (Campellone et al., 2006). The IRSp53 SH3 domain is represented by the 
similar PDB entry 2KXC. Regions of unknown structure are represented by ropes with end-to-end 
distances corresponding to root mean square end-to-end distances of random coils of the respective 
chain length (Tanford et al., 1966).  
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1.7 Outlook 
1.7.1 NPY motif containing host proteins may represent physiological ligands 
for IRSp53/IRTKS 
The emergency of the critically increasing incidence of antibiotic resistance due to the 
widespread and, to some extent, careless use of antibiotics requires a more detailed 
understanding of the molecular basis of host pathogen interactions to generate alternative 
methods to treat infectious diseases. Moreover, diseases like the HUS, described to be 
triggered by the use of antimicrobial substances (see section 1.1.4.2), currently lack a well-
established method of treatment and rely on the development of such alternative strategies. 
Structural insights into the key mechanisms of infection of human pathogenic E. coli can 
pave the way to design inhibitors to disrupt key interactions during infection and enable the 
treatment of infectious diseases without the use antibiotics.  
Several studies already aim at the development of strategies to neutralise Shiga toxins or to 
disrupt the mechanism of adhesion of human pathogenic bacteria like blocking the 
interaction of Tir:intimin of intimin positive EHEC. However, the Tir:IRSp53 interaction 
currently seems to be no drug target to treat EHEC infections as this interaction seems to 
trigger only actin polymerisation. Inhibition of actin polymerisation and thus pedestal 
formation after EHEC infection might, to some extent, probably improve absorption and 
reduce intestinal tissue damage and the dissemination of EHEC, which is suggested to be 
enhanced by the pedestals which move along the cell surface, the so-called ‘pathogen 
surfing’. But, according to the current knowledge, inhibited pedestal formation will probably 
not affect adhesion or toxin production of EHEC, the central issue of EHEC infections. 
Nevertheless, unveiling the molecular mechanism of pedestal formation and the investigation 
of the bacterial benefit of this feature will contribute to the substantial understanding of EHEC 
infections and hence the development of strategies to treat this disease.  
The data of this study characterise the NPY motif of Tir as a ‘hot spot’ for the interaction with 
the host’s IMD. The domain seems to be evolutionary evolved to recognise this motif, a 
feature that becomes usurped by pathogenic E. coli, and it is tempting to speculate that this 
binding site may have cellular ligands that harbour NPY motifs, which occur in up to 3% of 
human proteins. The huge variety of possible ligands to this binding site of the host’s IMD 
illustrate again, that even if the IMD:Tir interaction represented a pharmacological relevant 
drug target, which is currently not the case, the Tir binding pocket of IMD seems to be 
inappropriate due to the presumably adverse effects by blocking also diverse cellular ligands. 
But interestingly, among these NPY motif containing proteins, numerous candidates can be 
found that are related to cellular processes that may involve IRSp53 or IRTKS (see Table 
1.7-1). Thus the discovery and characterisation of this new binding pocket may lead to the 
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identification of new interaction partners, possibly involved in the pathogenesis and 
cytoskeletal regulation. Furthermore, these studies will also contribute to a better 
understanding of the cellular role of IRSp53. It will be an exciting task to probe these 
interactions and analyse the recently described IRSp53 knockout mouse (Sawallisch et al., 
2009) for potential phenotypes that may relate to defective IMD:NPY interactions.  
 
Table 1.7-1: Potential NPY-containing interactors of IMD proteins. The SwissProt database 
comprises 20,329 human proteins, of which 749 contain the NPY motif as detected using Scansite 
(http://scansite.mit.edu/dbsequence_one.html). Candidates that potentially might interact with the IMD 
of IRSp53 or IRTKS were selected according to the following criteria: (i) nuclear, intraluminal or 
extracellular motifs are excluded; (ii) the motif is conserved at least between human and mouse 
orthologs and (iii) conservation between paralogues is preferred. The selection shown is further 
confined based on involvement in IRSp53-signalling (e.g. Shank), in cytoskeleton reorganisation (e.g. 
LIMK), in Rho-GTPase signalling (Intersectin), and for those that were implicated in filopodium (or 
similar like stereocilia/microvilli, e.g. Myosin X) formation before (de Groot et al., 2011). 
Short name Full name 
NPY 
position 
NPY     
location 
Protein 
class 
PK3CB 
Pi3K, p110b, Phosphtidylinositol-3 
kinase, catalytic subunit 
482-84 C2 domain 
phospholipid 
kinase 
ROCK2 Rho-associated protein kinase 2 1195-97 very C-terminus 
protein 
kinases 
LIMK1 & -2 LIM domain kinase 1 512-14 kinase domain 
ITSN1 & -2 Intersectin 1 (Cdc42 GEF) 1618-20 C2 domain 
regulators of 
Rho-GTPase 
activity ARHGAP10 
GRAF2 GAP10 associated with 
FAK (RhoA, Cdc42) 
625-27 
between Rho-
GAP and SH3 
Myo IA Brush border myosin 1 /BBM-I 49-51 head domain 
myosins 
Myo X Myosin 10  (filopodia) 104-06 head domain 
MyoXV Myosin 15 (stereocilia) 
423-25 
1263-65 
head domain NT 
head domain CT 
CLAP1 & -2 CLIP115 associated protein1 1265-67 CLIP-binding site 
microtubule 
tip proteins 
SHANK2 
SH3 and multiple ankyrin repeat 
domains protein 2 
608-10 central part 
partners of 
IRSp53  
BAI2 
Brain-specific inhibitor of 
angiogenesis 2 (GPCR) 
1417-19 cytoplasmic tail 
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1.7.2 The Tir:IMD interaction is likely to compete with membrane binding 
The cigar shaped IMD dimer possesses positively charged amino acids exclusively 
concentrated at the ends of IMD, interacting with high affinity to PI(4,5)P2, and localise the 
IMD to the plasma membrane (Mattila et al., 2007; Saarikangas et al., 2009). However, it is 
also shown that membrane binding is not required for the formation of pedestals by EHEC 
bacteria (Weiss et al., 2009). It would be interesting to examine whether the carboxy-terminal 
region of Tir competes with the membrane for IRSp53 binding or if membrane bound IRSp53 
is also capable to interact simultaneously with this Tir fragment. This could be examined by 
e.g. vesicle cosedimentation assays (Saarikangas et al., 2009), where the ability of labeled 
Tir to cosediment with membrane bound IMD would be examined. 
 
1.7.3 The binding affinity of Tir to IMD  
The quite low dissociation constant of 60 µM of the EHEC Tir:IMD interaction, measured by 
ITC, may be due to the use of a short peptide instead of the whole caboxy-terminal 
cytoplasmic Tir. As already discussed (section 1.6.5), the SH3 domain of IRSp53 as well as 
the avidity effect may contribute to this interaction and possibly dramatically increase the 
binding affinity. Thus, it would be exciting to test whether other regions of Tir and IRSp53 
also contribute to this interaction. Furthermore, it would be of interest to test the effects of 
IRSp53 mutants in physiological relevant cell culture models, as the pull down assays were 
performed using cell lysates and the PIP assays were performed in yeast. 
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2 Chapter II 
 
Structural Characterisation of Amorfrutins 
Bound to the Peroxisome Proliferator-
activated Receptor gamma 
 
 
2.1 Introduction 
2.1.1 The nuclear receptor PPARγ 
The peroxisome proliferator-activated receptor gamma (PPARγ) belongs to the so-called 
adopted orphan receptors of the nuclear receptor superfamily. The name is derived from the 
ability of the first identified member of this family, PPARα, responding, in contrast to the other 
family members, to various compounds that induce peroxisome proliferation (Tontonoz and 
Spiegelman, 2008). The PPARs exhibit distinct tissue distributions with different activities. 
PPARα is expressed in liver, kidney, heart, and muscle where it regulates fatty acid 
catabolism. PPARδ is ubiquitously expressed with less defined functions, but is implicated in 
e.g. wound healing and keratinocyte differentiation (Michalik et al., 2001). PPARγ, the target 
protein of this study, is mainly expressed in adipocytes and macrophages. PPARγ consists of 
an amino-terminal, ligand-independant activation function 1 (AF1), a DNA binding domain 
which is highly conserved among the superfamily, followed by a hinge region and a carboxy-
terminal conserved ligand-binding domain (LBD), containing the activation function 2 (AF2) 
(Figure 2.1-1A) (Evans, 1988; Glass and Ogawa, 2006). PPARγ acts in the nucleus as a 
heterodimer with the retinoid X receptor RXRα and is a ligand-activated transcription factor 
(Berger and Moller, 2002), interacting with food ingredients like fatty acids and their 
metabolites (Figure 2.1-1B) (Kliewer et al., 1997; Tontonoz and Spiegelman, 2008). PPARγ 
is a well-known drug target of e.g. type II diabetes treatment as it works as a dominant 
sensor and regulator in adipose cell differentiation and glucose and lipid metabolism, but 
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plays also a key role in inflammation, atherosclerosis and cancer, and has strong anti-growth 
properties (Murphy and Holder, 2000; Tontonoz and Spiegelman, 2008). 
 
 
Figure 2.1-1: Domain organisation of PPARγ and the structural characteristics of its LBD. (A) 
PPARγ consists of an amino-terminal activation function domain 1 (AF1), a central DNA-binding 
domain, and a carboxy-terminal ligand-binding domain (LBD) (Glass and Ogawa, 2006). (B) PPARγ 
and the mechanism of DNA binding according to Glass and Ogawa (2006). PPARγ heterodimerises 
with RXRα and binds to DNA in a ligand-dependant manner. (C-E) The protein surface and ribbon 
representation of PPARγ’s LBD reveal a huge ligand entry site in the lower portion of the protein, 
located between helix H3 and H2’. (D) The receptor dynamic is illustrated by plotting the temperature 
factors (B-factors) on the structure (PDB 1PRG), revealing the omega loop and helix H12 as the most 
mobile segments of the LBD. The phosphorylation site at Ser245 (Ser273 in PPARγ2), and helix H12 
are highlighted. (E) The huge ligand binding cavity of PPARγ is illustrated by white surfaces (Nolte et 
al., 1998).  
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2.1.1.1 The activation function 1 (AF1) 
The amino-terminal AF1 of the nuclear receptor is different in two isoforms of PPARγ. In 
contrast to PPARγ1, PPARγ2 has 28 additional amino acids at the amino-terminus. It is 
expressed in a more adipose-selective manner and about ten times more abundant than 
PPARγ1 (Tontonoz et al., 1994). Furthermore, PPARγ2 appears to be more potent to induce 
adipogenesis (Rosen et al., 2002). MAP kinase (specifically Erk1, also known as p44) 
mediated phosphorylation of AF1’s Ser112 reduces ligand-binding affinity of the receptor and 
negatively regulates the transcriptional activity, resulting in the inhibition of its biological 
action (Adams et al., 1997; Hu et al., 1996). The phosphorylation was suggested to induce a 
conformational change of the unbound receptor, in which the amino-terminal AF1 inhibits, via 
intramolecular interactions, ligand binding to the LBD (Shao et al., 1998). The AF1 was also 
shown to bind to PPARγ co-activator 2 (PGC-2), not affected by Ser112 phosphorylation, 
which itself exhibits pro adipogenic action (Castillo et al., 1999). However, the exact 
mechanism of AF1 mediated regulation of PPARγ’s adipogenic action remains still elusive 
and requires further investigation. 
 
2.1.1.2 The ligand-binding domain (LBD) 
The LBD has several regulator functions. It determines the subcellular localisation, initiates 
heterodimerisation with RXRα and regulates the transcriptional activation or repression in a 
ligand-dependant manner. The LBD consists of 13 α-helices and a small four-stranded β-
sheet region (Figure 2.1-1D). The AF2, the receptors surface facilitating co-activator 
interaction, is formed by the LBD’s helix 3-4 loop and the carbox-terminal ends of helix H11 
and H12. The LBD has a phosphorylation site at Ser245 (Ser273 in PPARγ2) (Choi et al., 
2010) and possesses a cavity of about 1300 Å³ in the lower portion of the LBD (Nolte et al., 
1998), located between helix H3 and the β-sheet region (Figure 2.1-1C-E).  
Ligand binding to the LBD of the nuclear receptor leads to co-activator recruitment. Co-
activators like the Steroid receptor co-activator-1 (SRC1) or the Peroxisome proliferator-
activated receptor gamma co-activator-1 alpha (PGC-1α) possess an LXXLL motif (where L 
is leucine and X is any amino acid) that dock with their hydrophobic sides, formed by the 
leucine residues, into a hydrophobic groove on the surface of the receptor (Figure 2.1-2) 
(Heery et al., 1997; Li et al., 2008; Nolte et al., 1998). A positively charged lysine (K301) and 
a negatively charged glutamic acid (E471) residue at each side of the hydrophobic groove 
contribute to the selectivity by clamping the LXXLL motif by hydrogen bonds with the motif’s 
backbone at both, the amino- and carboxy-terminal ends (Darimont et al., 1998; Nolte et al., 
1998; Shiau et al., 1998). This kind of interactions of the hydrophobic groove with the co-
activator motif leads to the name ’charge clamp‘. In the unbound state, nuclear receptors are 
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frequently blocked by co-repressors like the silencing mediator co-repressor for retinoid and 
thyroid-hormone (SMRT) or the nuclear receptor co-repressor (N-CoR) (Chen and Evans, 
1995; Horlein et al., 1995) containing an LXX[I/H]IXXX[I/L] motif (Hu and Lazar, 1999; Nagy 
et al., 1999; Perissi et al., 1999). The ligand dependant distinction between co-repressor and 
co-activator was proposed to be caused by the different length of the motifs that have to be 
accommodated in the binding pocket. Ligand binding leads to a conformational change in 
which the amphipathic helix H12 is stabilised tightly packed against the LBD (see also 
section 2.1.1.3) and shortens the hydrophobic groove, such that it only suits the smaller co-
activator motif (Perissi et al., 1999). 
 
 
Figure 2.1-2: Complex of PPARγ’s LBD with an SRC1 peptide. The SRC1 peptide (red) interacts 
with the charge clamp of the LBD (PDB 2PRG) in response to a ligand like rosiglitazone. The 
accessibility of the charge clamp is regulated by helix H12 (yellow) in a ligand dependant manner. 
Residues defining the charge clamp are indicated. Residues in parentheses correspond to residues in 
PPARγ2.  
 
2.1.1.3 Ligand-mediated LBD stabilisation regulates PPARγ’s transcriptional 
activity 
Crystallographic temperature factors (B-factors) are linearly related to the mean square of an 
atom’s displacement and indicate atomic flexibility. Crystal structures of unbound PPARγ 
have high temperature factors in their lower portion (Figure 2.1-1D), which thus seems to be 
less rigid than the upper portion. Helix H12 is the most mobile helix and the omega-loop, 
linking helix H2’ and helix H3, is the most mobile loop (Nagy et al., 1999; Nolte et al., 1998). 
Both elements are located in the lower portion. Ligand binding to PPARγ reduces atomic 
thermal vibrations and stabilises the receptor. This stabilisation induces a conformational 
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change of helix H12, leading to a tight association of this helix to the LBD and results in a 
more compact and rigid structure (Choi et al., 2010; Nagy and Schwabe, 2004). This affects, 
as described above, co-regulator recruitment. The ligand dependant degree of LBD 
stabilisation is believed to be directly proportional to the receptors transcriptional activity 
(Nagy and Schwabe, 2004) and may cause differential co-regulator recruitment (Choi et al., 
2010). Stabilisation can be achieved by direct contacts of the ligand to helix H12, as shown 
for full agonists like rosiglitazone (see Figure 2.1-4 and section 2.1.1.3.1), or by a helix H12 
independant stabilisation, as shown for partial and intermediate agonists like the non-
thiazolidinedione selective partial agonist (nTZDpa) and BVT.13 (see Figure 2.1-3 and 
section 2.1.1.3.2). However, both mechanisms of stabilisation result in a similar position of 
helix H12. 
 
 
Figure 2.1-3: The PPARγ partial agonist nTZDpa and the intermediate agonist BVT.13. 
 
2.1.1.3.1 The PPARγ full agonist rosiglitazone 
The synthetic compound rosiglitazone belongs to the group of thiazolidinediones (TZDs) and 
is a potent, high-affinity PPARγ activator, which is used as insulin sensitizer to treat type II 
diabetes. The small, lipophilic rosiglitazone molecule targets adipose tissue where PPARγ is 
mainly expressed and stabilises preferentially helix H12 by direct contacts (Figure 2.1-4A). 
This kind of stabilisation leads to co-activator recruitment and is suggested to ‘freeze’ the 
receptor in a rigid conformation. Obesity-induced Cdk5-mediated phosphorylation of the 
receptor LBD’s Ser245 is thereby inhibited (Choi et al., 2010). The inhibition of the 
phosphorylation is apparently closely associated with the anti-diabetic effects of 
rosiglitazone, as it alters the expression of a subset of genes with regulatory functions in 
metabolism, like an enhanced transcription of the insulin-sensitising adipokine, adiponectin 
(Choi et al., 2010). Rosiglitazone is currently used to treat type II diabetes, but causes 
adverse effects including weight gain, oedema, and congestive heart failure (Kahn and 
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McGraw, 2010; Lebovitz, 2002). These adverse effects rationalise research to explore new 
agonists for PPARγ which also induce insulin sensitivity but lack these adverse effects. 
 
2.1.1.3.2 PPARγ partial and intermediate agonists 
Full, intermediate, and partial agonists are defined by transcriptional activation potentials of 
>80%, 50-80%, or <50%, relative to the full agonist rosiglitazone. In contrast to full agonists, 
intermediate and partial agonists like BVT.13 and nTZDpa or MRL-24 (see Figure 2.1-4) do 
not stabilise helix H12 by direct contacts but rather globally stabilise the LBD by contacts to 
helix H3 and the β-sheet region of the binding pocket in the lower portion of the domain 
(Figure 2.1-4) (Bruning et al., 2007). The mode of stabilisation of the receptor by partial 
agonists leads to a more effective inhibition of Ser245 phosphorylation and to a more specific 
and in general reduced gene activation profile, compared with the full agonist rosiglitazone. 
These effects were already described for the partial agonist MRL-24 (Choi et al., 2010). 
Partial agonists, also known as selective PPARγ modulators (SPPARγMs) are able to 
separate adverse effects like adipogenesis from inducing insulin sensitivity in vivo (Rangwala 
and Lazar, 2002).  
 
 
Figure 2.1-4: Ligand dependant stabilisation of the LBD. LBD stabilisation by the full PPARγ 
agonist rosiglitazone (A) and the partial agonist MRL-24 (B) according to the hydrogen/deuterium 
exchange data of Choi et al. 2010. The LBD’s stabilised regions are coloured blue. Helix H12, H3, and 
the phosphorylation site are indicated. Note the differentially stabilisation of helix H12 and the omega 
loop, containing the phosphorylation site. 
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Co-activators like SRC-1 are known to bind to the charge clamp at helix H12 in response to 
ligands like the full agonist rosiglitazone. But, as there are no significant conformational 
differences observed between the LBD bound to full, intermediate or partial agonists, it was 
suggested that the differentially stabilisation of the receptor and in particular the diminished 
stabilisation of helix H12 by partial agonists is reasonable for the reduced and more specific 
gene activation profile. Furthermore, the phosphorylation of Ser245 on the opposite site of 
the domain may constitute a second ligand-gated co-regulator binding site near this residue 
(Choi et al., 2010). The differentially regulation of this phosphorylation site by partial or 
intermediate agonists may thus also affect co-regulator recruitment. Agonists with the 
potential to induces insulin sensitivity with milder or even without the induction of adverse 
effects may pave the way to more specific PPARγ activation for the clinically use as 
therapeutic drugs to treat diseases like type II diabetes, while maintaining the patients quality 
of life. 
 
2.1.1.4 Co-regulator recruitment 
It was suggested that distinct ligands generate by differential stabilisation unique co-
activator-binding surfaces on the LBD, resulting in a differential recruitment of co-regulators 
and thus a different transcriptional activation by PPARγ (Choi et al., 2010; Kodera et al., 
2000; Wu et al., 2003). Furthermore, sequences flanking the LXXLL motif of the co-activator 
also affect the recognition by the receptor (Klein et al., 2005; Wu et al., 2003). These 
suggestions are further supported by the findings that PGC-1α is able to act as a co-activator 
of PPARγ in the presence or absence of rosiglitazone (Li et al., 2008; Wu et al., 2003). While 
the rosiglitazone-mediated co-activation is independant of the charge clamp mutation E471A, 
the ligand-independant activation is abolished by this mutation. This indicates a unique, 
ligand-dependant structural feature of the LBD that associates with PGC-1α (Wu et al., 
2003). On the contrary, the rosiglitazone mediated activation is inhibited by the PGC-1α 
mutant S(-2)A, with the -2 position relative to the first leucine of the 144LXXLL148 motif (Wu et 
al., 2003). Thus both, the ligand but also the co-activator configurations are critical for co-
regulator recognition and nuclear receptor activity. 
 
2.1.2 A new class of high affinity PPARγ partial agonists 
A new class of high affinity PPARγ partial agonists, the amorfrutins (see Figure 2.1-5), was 
identified by our cooperation partner, the group of Dr. Sascha Sauer, Max Planck Institute for 
Molecular Genetics, Berlin. They have screened a library of about 8000 pure natural 
products using an electrospray ionisation mass spectrometry based high-throughput 
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screening method and identified the amorfrutins as structurally new and affine PPARγ 
agonists. Amorfrutins are a group of natural products with the characteristics of SPPARγMs 
(Weidner et al., submitted). They are non-toxic ingredients of edible plant roots of liquorice, 
Glycyrrhiza foetida, and fruits of a related legume, Amorpha fruticosa, also known as desert 
false indigo or bastard indigobush. The name ‘amorfrutin’ is derived from Amorpha fruticosa, 
in which the molecules were originally identified. Amorfrutins are selective and high affinity 
PPARγ agonists with dissociation constants for amorfrutin 1, 2, and B of about 20-300 nM, 
determined by time resolved FRET assays. The small, lipophilic amorfrutin molecules consist 
of a 2-hydroxy benzoic acid core structure with diverse phenyl and isoprenyl moieties. 
Amorfrutin 1 was shown to increase insulin sensitivity without the induction of adipogenesis 
and even lead to weight loss in vivo (Weidner et al., submitted). Amorfrutins have great 
potential for treatment or prophylaxis of type II diabetes and the metabolic syndrome in 
general. 
 
 
Figure 2.1-5: Structures of amorfrutin 1, 2, and B, used in this study.  
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2.2 Aim of this work 
The aim of this work was to solve the crystal structures of amorfrutin 1, 2, and B in complex 
with the ligand-binding domain (LBD) of human PPARγ for structural characterisation of 
these novel natural products at the atomic level. Recent research regarding ligand specific 
selectivity, affinity, and transcriptional activation (Weidner et al., submitted) led to the 
assumption that different structural features of amorfrutins stabilise the transcriptional 
receptor. Structural comparison, also with related complex structures, should help to identify 
these features, elucidate the mechanism of activation, and classify, whether amorfrutins are 
full, intermediate, or partial agonists. Furthermore, the study should explain how the 
structural data will fit into the current working model of PPARγ activation. The results of this 
study should contribute to the understanding of the regulatory mechanism of PPARγ in 
insulin sensitisation and fat metabolism.  
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2.3 Materials 
If not stated otherwise, the materials used in this chapter are similar to the materials in 
chapter I. 
 
2.3.1 Plasmid for hPPARγ LBD expression 
A PCR fragment encoding amino acids 223-505 (AEIS...KDLY) of the LBD of hPPARγ 
(SwissProt PPARG_HUMAN P37231), cloned with NdeI and BamH1 into a pET-28a vector 
(Novagene), was used for expression, resulting in hPPARγ LBD fused to an amino-terminal 
His7-tag and thrombin cleavage site, with the sequence GSHMAEI...KDLY upon cleavage. 
 
2.3.2 Compounds 
The compounds amorfrutin 1 (NP-003520), amorfrutin 2 (NP-003521), and amorfrutin B were 
synthesized by Frank C. Schröder (Boyce Thompson Institute and Department of Chemistry 
and Chemical Biology, Cornell University, Ithaca, NY, USA) and obtained dissolved in DMSO 
at 100 mM. Higher concentrations of the amorfrutins couldn’t be achieved due to their 
solubility limits. 
 
2.4 Methods 
If not stated otherwise, the methods used in this chapter are similar to the methods in 
chapter I. 
 
2.4.1 Production and purification of PPARγ’s LBD 
The PPARγ LBD was expressed with a previously described expression plasmid kindly 
provided by Krister Bamberg (Cronet et al., 2001). Transformed BL21(DE3) cells were 
induced with 0.1 mM IPTG at 18°C for 20 h. Harvested cells were disrupted with a high 
pressure cell disrupter (Constant Systems) in 20 mM Tris-HCl, 150 mM NaCl, 10% (v/v) 
glycerol, 1 mM tris(2-carboxyethyl)phosphine HCl (TCEP, Gold Biotechnology), 10 mM 
imidazole, pH 8.0 in the presence of protease inhibitors (Complete EDTA-free, Roche) and 
centrifuged (35,000xg, 45 min). The supernatant was loaded on a 5 ml HisTrap HP column 
(GE Healthcare) and eluted with an imidazole gradient (10-300 mM imidazole) over 20 
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column volumes. The protein was diluted to a final concentration of 20 mM NaCl, 
immediately loaded onto a MonoQ HR 10/10 column (GE Healthcare) and eluted with a NaCl 
gradient (20-500 mM NaCl), followed by incubation with thrombin protease (1 U/mg) at 4°C 
for 20 h to cleave off the His-tag. His-tag peptides and uncleaved material were removed by 
rechromatography with Ni-NTA agarose (Qiagen), followed by gel filtration (HR 10/30 
Superdex 75 prep grade column, GE Healthcare) in 20 mM Tris-HCl, 100 mM NaCl, 0.5 mM 
DTT, and 2 mM EDTA, pH 8.0. 
 
2.4.2 Analytical methods 
Photometric quantification of protein concentrations, SDS-PAGE, DLS, and MS were carried 
out in accord with the description in chapter I (see section 1.4.3). 
 
2.4.2.1 Analytical gel permeation chromatography 
Analytical gel permeation chromatography was performed in 20 mM Tris-HCl, 100 mM NaCl, 
0.5 mM DTT, and 2 mM EDTA, pH 8.0 using a HiLoad 16/60 Superdex 75 column (GE 
Healthcare). 1 ml buffer containing a protein mixture of 20 mg/ml ribonuclease A (14.6 kDa), 
20 mg/ml ovalbumin (46.7 kDa), and 10 mg/ml thyroglobulin (699 kDa) was applied to the 
column and used as molecular weight standard. The gel-phase distribution coefficient (Kav) 
was calculated according to Equation 2.4-1, where V0 is column void volume, Ve is elution 
volume, and Vc is geometric column volume, calculated from column dimensions. V0 was 
approximated from the elution volume of thyroglobulin. Kav was plotted versus the logarithm 
of the molecular weight of the different standard proteins. The equation of the linear fit of the 
relationship between Kav and the different molecular weights of the standard proteins was 
calculated and used to estimate the molecular weight of LBD. 
 
    
     
     
 
Equation 2.4-1 
 
 
2.4.2.2 AF4 and DLS 
Protein samples of the LBD were analysed by Asymmetric Flow Field-Flow Fractionation 
(AF4), coupled to a dynamic light scattering (DLS) device, in-house by Dr. Thorsten Lührs. 
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2.4.3 Crystallisation by vapour diffusion 
2.4.3.1 Sitting-drop vapour diffusion 
The sitting-drop vapour diffusion method was used for initial screening in 96-well format as 
described in chapter I (see section 1.4.4.1). 
 
2.4.3.2 Hanging-drop vapour diffusion 
The protein was concentrated to 11 mg/ml and crystallised using hanging drop-vapour phase 
diffusion by mixing equal volumes of concentrated protein and reservoir solution (0.8 M tri-
sodium citrate and 0.1 M imidazole, pH 8.0). Crystals appear after 2-5 days at 19°C. 
 
2.4.3.3 Crystal soaking 
Soaking crystals with the different amorfrutins was carried out using crystals grown under 
conditions described in section 2.4.3.2. The crystals were transferred into soaking buffer (10 
mM Tris-HCl, 50 mM NaCl, 0.25 mM DTT, 1 mM EDTA, 0.8 M M tri-sodium citrate, 0.1 M 
imidazole, final pH 8.0) with a stepwise increase in reagent concentration (0.5 mM, 1 mM, 
and 1.5 mM ligand and a maximum of 1.5% DMSO) with varying incubation times. 
 
2.4.3.4 Co-crystallisation 
The complexes of the PPARγ LBD bound to the different amorfrutins were prepared by 
adding a 10-fold molar excess of each amorfrutin to the purified LBD at a final concentration 
of 1 mg/ml. DMSO and unbound ligand were removed by using a HR 10/30 Superdex 75 
prep grade column (GE Healthcare) in 20 mM Tris-HCl, 100 mM NaCl, 0.5 mM DTT, and 2 
mM EDTA, pH 8.0. The complexes were crystallised using the hanging-drop vapour diffusion 
method according to section 2.4.3.2, but had to be optimised by microseeding (see section 
1.4.4.3). 
 
2.4.4 Data collection, structure determination and refinement 
To prevent or minimise crystal damage by radiation, the crystals were transferred into a mild 
hypertonic cryo-protectant solution (0.84 M tri-sodium citrate, 25% (v/v) glycerol, and 0.1 M 
imidazole, pH 8.0) and immediately thereafter flash frozen in liquid nitrogen before data 
collection at 100 K. The data sets were collected in-house on a Saturn 944+ detector 
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(Rigaku) using Cu Kα X-rays from a Rigaku MicroMax-007 HF rotating-anode X-ray 
generator with a VariMax Optic (Rigaku). Images were indexed and processed with XDS 
(Kabsch, 1993) and the structures were solved by molecular replacement using CCP4 
MOLREP (Vagin and Teplyakov, 1997) with PDB entry 1PRG (Nolte et al., 1998) as the 
search model. REFMAC5 (Murshudov et al., 1997) and Phenix.refine (Adams et al., 2010) 
were used for refinement. TLS (translation/libration/screw) parameters (Painter and Merritt, 
2006) were included to allow domain movements to be refined and Coot (Emsley and 
Cowtan, 2004) was used for manual model building. Figures were prepared with PyMOL. 
Root mean square deviations (r.m.s.d.) between common Cα-positions were calculated with 
ProFit using the McLachlan algorithm (McLachlan, 1982). The validation of the structure was 
performed using MolProbity (Chen et al., 2010; Davis et al., 2007). 
 
2.4.5 Bioinformatics 
Structural analysis and figure preparations were carried out according to chapter I (see 
section 1.4.6). 
 
2.4.5.1 Sequence analysis 
Protein sequences were aligned with ClustalW2 (Larkin et al., 2007) and displayed with 
ESPript 2.2 (Gouet et al., 2003). 
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2.5 Results 
2.5.1 Production and purification of the PPARγ ligand-binding domain (LBD) 
The PPARγ LBD was expressed and purified according to section 2.4.1, using IMAC as the 
initial purification step. The LBD was eluted from the matrix using a gradient up to 300 mM 
imidazole. The protein was already completely eluted after 130 mM imidazole (Figure 2.5-1). 
The yield of IMAC purified PPARγ LBD was about 70 mg/L culture. 
 
 
Figure 2.5-1: IMAC purification of the PPARγ LBD. Bacterial lysate containing the LBD was loaded 
on a 5 ml HisTrap HP column and eluted with a gradient of 10 to 300 mM imidazole (A). The grey and 
green line depicts the fractions analysed by SDS-PAGE and Coomassie Blue staining (B). The 
fractions marked green were pooled for further purification. M: protein standard. 
 
 
Figure 2.5-2: Anion exchange purification. The PPARγ LBD purified by IMAC was loaded on an 
anion exchange MonoQ HR 10/10 column and eluted with a gradient of 20 to 500 mM NaCl (A). The 
green line marks the fractions analysed by SDS-PAGE and Coomassie Blue staining (B). The marked 
fractions were pooled for further processing. M: protein standard. 
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The LBD was further purified and concentrated by anion exchange chromatography. It was 
eluted early in a gradient of 20 mM to 500 mM NaCl (Figure 2.5-2). The ion exchange 
chromatography leads to a high purity of the protein, which was subsequently digested using 
thrombin protease to cleave off the His7-tag (Figure 2.5-3). IMAC Rechromatography with Ni-
NTA superflow was used to remove the His-tag peptide and uncleaved material. Gel filtration 
was used for final purification and buffer exchange (Figure 2.5-4). 
 
 
Figure 2.5-3: SDS-PAGE verifying successful removal of the approximately 3 kDa His7-tag. M: 
protein standard. 
 
 
Figure 2.5-4: Gel filtration. The LBD of PPARγ elutes at 71 ml from a Superdex 75 HR 16/60 column 
(A). The grey and green lines depict the fractions analysed by SDS-PAGE (B), whereas the fractions 
marked green were pooled. Arrows indicated artefacts of the gel electrophoresis. M: protein standard. 
 
SDS-PAGE of the gel filtration fractions resulted in two additional bands at 75 kDa and 250 
kDa next to the expected 32.7 kDa LBD band. Mass spectrometry, analytical gel filtration as 
well as AF4, coupled to DLS, were carried out to identify these additional bands. Mass 
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spectrometry, performed in-house by Dr. Manfred Nimtz and Undine Felgenträger, showed 
that all three bands consisted of hPPARγ LBD. Furthermore, analytical gel filtration and AF4-
DLS both revealed a monodisperse protein solution (Figure 2.5-4A and Figure 2.5-5). 
Analytical gel filtration, using thyroglobulin to approximate the void volume of the column and 
ovalbumin as well as ribonuclease A as molecular standards, resulted in a single peak with a 
calculated molecular weight of about 40 kDa (Figure 2.5-4A and Figure 2.5-5A,B). The AF4-
DLS, as the much more precise method, was carried out in-house by Dr. Thorsten Lührs and 
revealed unambiguously a monodisperse protein solution and the exact molecular weight of 
32.6 kDa for the LBD (Figure 2.5-5C). These data verify the desired purity and 
monodispersity of the monomeric protein in solution and confirm an artificial oligomerisation 
of the protein during the SDS-PAGE, due to the formation of stable multimers under the 
condition of the SDS-sample-buffer used for the SDS-PAGE. 
 
 
Figure 2.5-5: Monodispersity of the purified LBD of PPARγ. Elution profile of the analytical gel 
filtration (A) and the derived standard line (B). The standard line was calculated from ovalbumin and 
ribonuclease A elution volumes. Thyroglobulin was used to approximate the column’s void volume. 
Using the standard line, a molecular weight of about 40 kDa was derived for the LBD. (C) AF4-DLS 
profile of the LBD. Shown are UV absorbance (continuous lines) and the molar mass (dashed lines) as 
a function of time. The analyses were performed using different protein amounts: 10 µg (red lines), 20 
µg (blue lines), and 50 µg (green lines), and reveal the exact molecular mass of the LBD (32.6 kDa). 
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2.5.2 Crystallisation of PPARγ’s LBD with different amorfrutins 
Protein crystals of the LBD in complex with the different amorfrutins were obtained by crystal 
soaking (section 2.5.2.1) and co-crystallisation (section 2.5.2.2), respectively. 
 
2.5.2.1 Crystal soaking 
Crystal soaking is fast and more convenient for obtaining crystal structures of one protein 
with different ligands, as it requires only one crystallisation condition. Thus, crystallisation 
conditions for ligand-free PPARγ LBD were screened based on the previously published 
crystallisation conditions of this protein (Nolte et al., 1998) using the hanging-drop vapour 
phase diffusion method (section 1.4.4.2), but also using the sitting-drop vapour phase 
diffusion method in 96-well format and the JCSG screens (section 1.4.4.1). Protein crystals 
appeared only with sodium citrate as the precipitant. Crystallisation conditions were 
optimised to 0.8 M tri-sodium citrate and 0.1 M imidazole, pH 8.0 (section 2.4.3.2). Protein 
crystals appeared already after two days at 19°C. Within two weeks, some of the crystals 
grew up to large monoclinic crystals with edge lengths of about 400 µm (Figure 2.5-6). The 
protein crystals diffracted X-rays up to 2.0 Å resolution. 
 
 
Figure 2.5-6: Crystal of the ligand-free LBD of PPARγ. The scale bar corresponds to 200 µm.  
 
The amorfrutins were obtained dissolved in DMSO at a maximal concentration of 100 mM, 
due to their solubility limits. To avoid DMSO mediated crystal damage and to determine the 
maximal amorfrutin concentrations that could be used during the soaking, the effect of the 
organic solvent on crystal integrity was tested prior to the soaking of the compounds. 
The crystals were transferred into soaking buffer with different DMSO concentrations. After 
24 h incubation, damage of the crystals became visible at DMSO concentrations above 
1.5%, like rounded edges or crystal cracks (Figure 2.5-7A). These effects did not exacerbate 
even after three days of incubation. Thus, a maximum of 1.5% DMSO and hence a maximum 
CHAPTER II - RESULTS  81 
concentration of the amorfrutins of 1.5 mM was used during the stepwise soaking of the LBD 
crystals. However, crystal soaking with the different amorfrutins resulted in crystal damage 
even at 1.5% DMSO (Figure 2.5-7B) and a decreased diffraction from up to 2.0 Å to about 
2.5 Å, even at lower concentrations and varying incubation times. The resulting electron 
densities turned out to be too badly defined to identify the precise position and molecular 
interactions of the amorfrutins in the LBD.  
 
 
Figure 2.5-7: The effects of soaking on crystal integrity. (A) DMSO lead to rounded edges and 
crystal cracks at concentrations above 1.5% and an incubation time of 24 h. (B) The amorfrutins, 
dissolved in DMSO, lead to affected crystal integrity even at DMSO concentrations below 1.5% and 
varying incubation times. Crystal damages are indicated by arrows. 
 
2.5.2.2 Co-crystallisation  
In comparison to crystal soaking, much better data were obtained by co-crystallisation of 
amorfrutins with PPARγ. The complexes of the LBD bound to different amorfrutins were 
formed according to section 2.4.3.4. The crystallisation conditions were similar to the 
crystallisation of the ligand free protein, but resulted in adnate, distorted, and cracked 
crystals. However, the microseeding technique was used to optimise crystal quality, leading 
to diffraction up to 2.0 Å and a well-defined electron density map that allowed the precise 
definition of the amorfrutins in the ligand binding pocket of PPARγ and the description of all 
molecular interactions. 
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2.5.3 Structural characterisation of different amorfrutins in complex with the 
LBD of PPARγ 
The crystal structures of the LBD in complex with three different amorfrutins were solved by 
molecular replacement and were all refined at a resolution of 2.0 Å (Table 2.5-1). The 
electron density maps reveal clearly the canonical three layer α-helical sandwich composed 
of 13 α-helices and a small, four-stranded β-sheet (Figure 2.5-8). The structures are in 
accord with previously published PPARγ LBD structures (Bruning et al., 2007; Cronet et al., 
2001; Nolte et al., 1998) with a calculated r.m.s. deviation of 0.87 ± 0.09 Å to Protein Data 
Bank (PDB) entry 1PRG (258 common Cα-positions of chain A aligned). 
 
 
Figure 2.5-8: Structural comparison of the three amorfrutins bound to the LBD of PPARγ. (A) 
The aligned overall structures of the LBDs bound to the three amorfrutins are almost indistinguishable. 
Only amorfrutin B (orange sticks) is shown. The amorfrutins bind between the lower portion of helix H3 
and the β-sheet region. Helices (blue) and β-strands (green) are labelled H1 to H12 and S1 to S4, 
respectively. (B) Superimposition of the three amorfrutins in the binding pocket, generated by 
alignment of the three respective protein structures. Amorfrutin 1 (white), 2 (yellow), and B (orange) 
are shown as sticks. Only the amorfrutin B-bound domain is displayed as ribbons. (C) 2FO-FC electron 
density omit map calculated around amorfrutin 1, 2, and B, contoured at 1.0 σ. The amorfrutins 
dynamic is illustrated by plotting B-factors on the structures.   
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Table 2.5-1: Summary of crystallographic analysis. 
Data collection amorfrutin 1 amorfrutin 2 amorfrutin B 
Space group C121 C121 C121 
Cell dimensions a, b, c (Å)  92.81, 61.10, 
118.22 
92.29, 60.97, 
117.9 
92.14, 60.86, 
117.6 
Unique angle β (°)  102.78 102.65 102.58 
X-ray source  Rigaku MicroMax-007 HF 
Wavelength (Å)  1.5419 
Resolution range (Å)  27-2.0 27-2.0 29-2.0 
Last shell (Å)  2.15-2.00  2.10-2.00 2.10-2.00 
Rmerge (%)  10.7 (64.4) 10.9 (56.3) 8.7 (45.4) 
Observations  293322 (51030) 149072 (18878) 148018 (18473) 
Unique reflections  43633 (8488) 43005 (5857) 42829 (5697) 
Mean (I)/s.d. (I)  15.8 (3.1) 13.71 (2.82) 17.68 (3.41) 
Completeness  99.5 (99.8) 99.0 (99.5) 99.2 (97.7) 
Multiplicity  6.7 (6.0) 3.4(3.2) 3.5(3.2) 
Structure refinement     
  Resolution range (Å)  27-2.0 27-2.0 29-2.0 
  Rwork (%)  20.4 20.89 20.3 
  Rfree (%)  25.3 25.9 23.3 
Total number of     
  Non-hydrogen atoms  4554 4671 4670 
  Protein atoms  4299 4380 4339 
  Ligand atoms  75 44 60 
  Water molecules  180 247 271 
r.m.s.d.     
  Bond length (Å)  0.011 0.010 0.010 
  Bond angle (°)  1.240 1.219 1.186 
  Main chain B-factors (Å
2
)  39.1 37.9 39.0 
  Side chain B-factors (Å
2
)  42.2 41.3 42.3 
  Average B-factor protein atoms (Å
2
)  40.7 39.7 40.7 
  Average B-factor ligand atoms (Å
2
)  43.1 47.6 43.6 
  Average B-factor solvent atoms (Å
2
)  44.3 44.9 44.3 
Ramachandran statistics     
  Most favoured regions (%)  98.8 97.3 98.3 
  Allowed regions (%)  1.2 2.7 1.7 
  Disallowed regions (%)  0 0 0 
 
Values in parentheses are for the highest resolution shell. 
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All three complex structures had an asymmetric unit containing two amorfrutin molecules 
bound to one LBD homodimer of almost identical monomers. The structures of the two 
monomers, denoted chain A and B, differ due to crystal contacts. The two different 
conformations of the LBD chains, termed active and inactive, are commonly observed in 
PPARγ LBD structures (Cronet et al., 2001; Nolte et al., 1998). The inactive conformation 
(chain B) is caused by helix H12 of chain B forming crystal contacts with a neighbouring 
molecule that probably prevent it from moving into the active conformation like chain A (see 
also section 2.5.4). The active conformation of chain A is similar to the complexed receptor 
with the full agonist rosiglitazone and the co-activator SRC1 (Nolte et al., 1998) and is 
commonly regarded as a suitable model for PPARγ LBD activation. The following sections 
will therefore refer only to the complex in the active conformation. 
The electron density maps of each amorfrutin is well defined in the complex structures 
(Figure 2.5-8C) and clearly reveal their position in the cavity of the LBD. Corresponding to 
their related structures, the three amorfrutins are bound with almost identical localisation and 
orientation (Figure 2.5-8A and B). Whereas full agonists like rosiglitazone or MRL-20 
stabilise especially helix H12 of the LBD (Bruning et al., 2007; Nolte et al., 1998), the 
amorfrutins stabilise the receptor between helix H3 and the β-sheet region, close to the 
ligand entry site. This recognition of the amorfrutins by PPARγ is similar to the partial 
agonists nTZDpa and MRL-24, and also to the intermediate agonist BVT.13 (Bruning et al., 
2007). These ligands all stabilise helix H3 and the β-sheet with hydrogen bonds to Ser342 
and Arg288 and form similar extensive van der Waals contacts, most prominently to Ile341 of 
the β-sheet and Cys285 of helix H3 (Figure 2.5-9, Figure 2.5-10 and Figure 2.5-11A). The 
mechanism of stabilisation and the low transcriptional activation (<50%) compared to the full 
agonist rosiglitazone (Weidner et al., submitted) (Table 2.5-2), imply that these amorfrutins 
belong to the group of partial agonists. 
Despite their similar structures, the amorfrutins interact differently with the LBD. Arg288 of 
the amorfrutin 1-bound PPARγ adopts two alternative conformations (Figure 2.5-9A), which 
are also observed in nTZDpa-bound PPARγ, but not in the unbound structure (PDB entry 
1PRG), where Arg288 is hydrogen bonded to Ser289 (Figure 2.5-10). In the amorfrutin 1 
complex, Arg288 either interacts with Glu343 of the β-sheet and the ligand’s carboxyl group, 
or with Glu295 of helix H3 via hydrogen bonds. Arg288 and Ser342 thus form a bond 
network upon binding of amorfrutin 1 that, supported by extensive van der Waals contacts of 
the phenyl and isoprenoid moieties, stabilises helix H3 and the β-sheet and explains the high 
binding affinity of 236 nM (Figure 2.5-9A and Table 2.5-2). 
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Figure 2.5-9: Structural details of amorfrutins bound to the LBD of PPARγ. (A) Amorfrutin 1 
exerts a hydrogen-bonding network directly to Ser342 of the β-sheet region and Arg288 of H3. Note 
the alternative conformations of Arg288 (red arrows), stabilised by Glu291 and Glu343. (B, C) 
Amorfrutin 2 and B coordinate water molecules to form hydrogen-bonding networks between Arg288 
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of H3 and the β-sheet region, but also directly interact with Ser342. Additional hydrophobic 
interactions of amorfrutin B’s longer geranyl side chain to Arg288 are the likely cause of this ligand’s 
higher binding affinity and also prevent the formation of an alternative conformation of Arg288, as 
observed in the complex with amorfrutin 1. In the schematic diagrams of atomic interactions on the 
right, calculated using LIGPLOT (Wallace et al., 1995), the ligands and the residues of the binding 
pocket are drawn with black and orange bonds, respectively. Hydrogen bonds are depicted by dashed 
lines and van der Waals contacts are indicated by spoked arcs and atoms with spokes. Oxygen atoms 
are coloured red, nitrogen atoms blue and carbon atoms black. S: sheet, H: helix, L: loop. 
 
 
Figure 2.5-10: Comparison of previously published PPARγ structures. Shown are the unbound 
LBD of PPARγ (PDB 1PRG) with Arg288 hydrogen bonded to Ser289 (Nolte et al., 1998), the LBD in 
complex with the intermediate agonist BVT.13 (PDB 2Q6S), and the LBD in complex with the partial 
agonists nTZDpa (PDB 2Q5S) and MRL-24 (PDB 2Q5P) (Bruning et al., 2007). 
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Amorfrutin 2 and B also form direct hydrogen bonds to Ser342 of the β-sheet but fail to form 
a salt bridge to Arg288 and do not trigger the alternative conformation of this residue. The 
lack of this interaction results in a lower degree of stabilisation of the 2-hydroxy benzoic acid 
core of amorfrutin 2 and B, depicted by increased B-factors (see Figure 2.5-8). However, 
both ligands use the same residues of the LBD to form a water network that stabilises 
Arg288 of helix H3 (Figure 2.5-9B, C and Figure 2.5-11A), similar to the structure with 
BVT.13 of Bruning et al. (2007) (Figure 2.5-10). Amorfrutin 2 has a binding constant of 287 
nM, similar to amorfrutin 1 with 236 nM (Table 2.5-2), whereas binding of amorfrutin B is 
markedly stronger with a binding constant of 19 nM. 
Amorfrutin B’s  long meta-geranyl side chain at the 2-hydroxy benzoic acid core leads to 
additional hydrophobic contacts especially to Arg288 of helix H3 and to helix H4-5, compared 
with amorfrutin 1 and 2 (Figure 2.5-9 and Figure 2.5-11A). These additional contacts of 
amorfrutin B lead to reduced B-factor values of the meta-geranyl side chain (see Figure 
2.5-8) and likely prevent that Arg288 adopts the alternative conformation, required for direct 
contacts to the ligand’s carboxyl group. The additional hydrophobic contacts also explain the 
almost 12-fold higher binding affinity of amorfrutin B compared to amorfrutin 1 (Table 2.5-2). 
 
Table 2.5-2: Affinity constants (Ki) and transcriptional activation relative to rosiglitazone 
according to (
1
) Weidner et al. (submitted) and (²) Bruning et al., 2007. 
 PPARα 
Ki 
PPARδ 
Ki 
PPARγ 
Ki 
Relative 
transcriptional 
activation 
Amorfrutin 1 27 µM1 27 µM1 0.236 µM1 39%1 
Amorfrutin 2 25 µM1 17 µM1 0.287 µM1 30%1 
Amorfrutin B 2.6 µM1 1.8 µM1 0.019 µM1 n.a. 
nTZDpa n.a. n.a. 0.029 µM1 >50%² 
MRL-24 n.a. n.a. n.a. >50%² 
BVT.13 n.a. n.a. n.a. 50-80%² 
Rosiglitazone 7 nM1 n.a. 7 nM1 100%1 
n.a., not available 
 
Amorfrutins exhibit high selectivity for PPARγ, as shown for the three amorfrutins with a 
selectivity factor of 60 to 140 in comparison to the other PPAR subtypes. Even if the 
conservation of the residues of the lower portion of helix H3 and the β-sheet is quite low 
(Figure 2.5-11) most of the interactions to the amorfrutins should also be fulfilled by the 
residues of PPARα or PPARδ. However, the guanidinium group of the unconserved Arg288 
(Figure 2.5-11) seems to play a key role in amorfrutin binding and this feature cannot be 
satisfied by any other residue. Thus the missing conservation of Arg288 is most likely the 
reason of the high selectivity of the three amorfrutins to the PPARγ subtype.  
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Figure 2.5-11: PPAR sequence conservation. (A) Sequence alignment of the three human PPARs, 
PPARα, PPARγ, and PPARδ (SwissProt Q07869, P37231, Q03181). The sequence identity to PPARγ 
is 69% and 72% for PPARα and PPARδ, respectively. Red and white boxes highlight identical and 
similar residues, respectively. Hydrophobic contacts of amorfrutin 1, 2, and B to PPARγ are indicated 
by blue, red, and green lines, respectively, beneath the sequences. Hydrogen bonds to amorfrutin 1 
are indicated by black asterisks; hydrogen bonds to amorfrutin 2 and B are indicated by cyan 
asterisks. Ruler is given according to PPARγ PDB entry 1PRG. (B) Sequence conservation between 
the three different PPARs. Blue areas indicate identity, white areas similarity, and yellow areas 
represent differing residues. Similarity score is projected on the complex structure of the LBD with 
amorfrutin 1. 
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2.5.4 Crystallographic contacts of the inactive conformation lead to an 
artificial orientation and localisation of the amorfrutins 
The orientation and localisation of the amorfrutin complex structures seem to be unaffected 
by crystallographic contacts in the active conformation. The inactive conformation (chain B), 
however, is obviously altered due to several contacts to a crystallographic related molecule. 
Helix H12 of chain B forms crystal contacts with chain A’s charge clamp of a neighbouring 
molecule and protrudes from the molecule, as it was observed in other PPARγ structures 
before (Cronet et al., 2001; Nolte et al., 1998). Helix H12 of chain B thereby occupies the 
charge clamp into which co-activator peptide binds, thus mimicking the two-turn, amphipathic 
co-activator α-helix (Figure 2.5-12) (Pochetti et al., 2007). Hence, chain B shows an artificial 
conformation. Chain A corresponds to the complex structures with co-activator peptides and 
therefore acts commonly as a model for PPARγ LBD activation. But also the omega loop 
linking H2’ and H3, the most thermally mobile loop of PPARγ’s LBD, forms crystal contacts 
with a related molecule. This loop is stabilised close to the ligand entry side by a hydrogen 
bond between the carbonyl of Lys265 and the nitrogen of Leu311 of the crystallographic 
related molecule (Figure 2.5-13A). Thereby the loop occludes parts of the ligand entry site of 
the inactive form, with His266 and Phe264 pointing into the pocket and to the amorfrutins, 
leading to an energetically unfavourable position of the ligands. Hence, the amorfrutins 
delocalise and rotate by almost 180° in the cavity, compared to the active state (Figure 
2.5-13B), except amorfrutin 1 that exhibits an alternative conformation in the inactive state. 
 
 
Figure 2.5-12: Crystallographic contacts mimic a co-activator peptide. Cartoon representation of 
PPARγ’s active chain A (blue), interacting with chain B of a symmetry related molecule (orange). Helix 
H12 of chain B occupies the charge clamp of chain A, thus mimicking a co-activator peptide like SRC1 
(red). SRC1 peptide is shown as it lies in the active conformation of the ternary complex with 
rosiglitazone (PDB 2PRG), generated by superimposition. Helix H12 of active chain A is drawn in 
yellow. Ribbon diagram is only shown for the complex structure with amorfrutin B. 
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Figure 2.5-13: Crystallographic contacts in the inactive conformation lead to an artificial 
orientation and localisation of the amorfrutins. (A) surface and ribbon representation of PPARγ`s 
ligand entry site of the inactive conformation with amorfrutin B (orange) as it lies in the active 
conformation, generated by superimposition. Interactions of a crystallographically related LBD 
molecule in a different homodimer (green) stabilise the loop linking H2’ and H3 (yellow) in front of the 
ligand entry side of the inactive state with His266 and Phe264 pointing into the pocket and to the 
amorfrutins as they lie in the active conformation. Residues involved are labelled. Oxygen atoms are 
coloured red and nitrogen atoms blue. Hydrogen bonds are shown as black dashed lines. (B) 
Localisation of amorfrutin 1 (white), 2 (yellow), and B (orange) in the active and inactive conformation 
of the LBD homodimer. Note the rotation of the amorfrutins in the inactive conformation by almost 
180°, except for amorfrutin 1 (white), showing an alternative conformation. Ribbon diagram is only 
shown for the amorfrutin B bound form. 
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2.6 Discussion 
2.6.1 Structural insights into amorfrutin recognition by PPARγ 
The crystal structures presented here structurally characterise amorfrutin 1, 2, and B, 
members of a novel class of natural products derived from non-toxic, edible plant roots that 
possess the ability of a selective PPARγ modulator to separate insulin-sensitisation from 
adipogenesis (Weidner et al., submitted). In cooperation with the group of Dr. Sascha Sauer 
(Max Planck Institute for Molecular Genetics, Otto Warburg Laboratory, Berlin, Germany) we 
identify the three amorfrutins as partial agonists as they show a transcriptional activation of 
PPARγ below 50% compared to the full agonist rosiglitazone (Weidner et al., submitted) 
(Table 2.5-2) and interact with the nuclear receptor via a helix H12 independant mechanism 
by stabilising helix H3 and the β-sheet region, similar to other partial or intermediate agonists 
of PPARγ (Bruning et al., 2007). 
This study shows that the amorfrutin 1, 2, and B bind, due to their structural similarity, with 
almost identical localisation and orientation close to the ligand entry site of the LBD. All three 
amorfrutins form extensive van der Waals contacts with the LBD via their isoprenoid, phenyl 
and aliphatic moieties, most prominently to Ile341 of the β-sheet S3 and Cys285 of helix H3. 
All three ligands engage a hydrogen bond network including Arg288 of helix H3 and Ser342 
of the β-sheet region. Amorfrutin 1 utilises only its carboxyl group for a direct hydrogen bond 
to Ser342 and to an alternative conformation of Arg288. Amorfrutin 2 and B utilise also their 
ortho-hydroxyl group to contact Arg288 and Ser342. However, amorfrutin 2 and B do not 
directly interact with Arg288 and thus do not induce an alternative conformation of this 
residue’s side chain, but utilize a water-mediated hydrogen bond to Arg288 instead (Figure 
2.5-9). 
The carboxyl group of the amorfrutins, interacting with the main chain nitrogen of Ser342 
and, as shown for amorfrutin 1, the guanidinium group of Arg288, seems to be reasonable 
for their high affinity. This is supported by a dramatically increased binding constant from 590 
nM to 23 µM upon esterification of the acidic head group of the structurally related amorfrutin 
5 (Figure 2.6-1) (Weidner et al., submitted). 
Regarding the selectivity of amorfrutin 1, 2, and B for PPARγ (60- to 140-fold) over PPARα or 
PPARδ, Arg288, and in particular its guanidinium group that interacts with the ligands 
carboxyl or hydroxyl, seems to play the most important role. Arg288 is not conserved among 
the PPARs. PPARα and PPARδ have a threonine at this position, which cannot interact with 
the amorfrutins in a similar way to arginine. This suggestion is further supported by a 
reduced affinity of a naturally occurring PPARγ mutant (R288H) to naturally ligands like the 
15-Deoxy-Delta-12,14-prostaglandin J2 (15d-PGJ2) or the fatty acid (9S)-9-
Hydroxyoctadeca-10,12-dienoic acid (9(S)-HODE) in comparison to rosiglitazone (Sarraf et 
al., 1999). Both, 15d-PGJ2 and 9(S)-HODE are shown to use Arg288 for excessive 
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hydrophobic interactions or hydrogen bondings, respectively (Itoh et al., 2008; Waku et al., 
2009), in contrast to the synthetic agonist rosiglitazone (Nolte et al., 1998). Furthermore, 
hydrogen bonds of the three amorfrutins to the β-sheet region, like the interaction to Ser342, 
are only dependant on main-chain atoms. Thus these interactions will probably be 
accomplished by other amino acids, like by the alanine of PPARα and PPARδ at this 
position. And even Glu343 which is an asparagine or tyrosine in PPARα and PPARδ, 
respectively, does not seem critical for the recognition, as the side-chain protrudes away 
from the ligand. 
 
 
Figure 2.6-1: Esterification of amorfrutin 5. Amorfrutin 5 (A) has a 40-fold higher affinity constant to 
PPARγ compared to its methylester (B) (Weidner et al., submitted).  
 
2.6.1.1 Structural comparison with other related PPARγ ligands 
Comparison of amorfrutin 1, 2, and B with the previously published partial PPARγ agonists 
nTZDpa and MRL-24 as well as with the intermediate agonist BVT.13 reveals a closely 
related interaction mode. All these ligands bind at almost the same site and similarly stabilise 
helix H3 and the β-sheet. Furthermore, all these ligands contain a carboxyl group that directly 
interacts with the Ser342 of the β-sheet and, with the exception of amorfrutin 1, implicate 
water molecules for further stabilisation. 
The nTZDpa interacts, similar to amorfrutin 1, via its carboxyl group with both, Ser342 and 
Arg288 in the alternative conformation (Figure 2.5-9A and Figure 2.5-10). Both ligands were 
described to be capable of avoiding adverse effects like adipogenesis while improving insulin 
sensitivity in vivo (Berger et al., 2003)(Weidner et al., submitted) and thus have a high 
potential as drugs to treat type II diabetes without inducing fat storage. 
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2.6.1.2 Possible mechanism of differential co-regulator recruitment 
The structure of the ternary complex of PPARγ, RXRα and DNA revealed three distinct 
interfaces (Chandra et al., 2008). The DNA binding and ligand-binding domains of the two 
proteins interact with each other. In addition, the LBD of PPARγ faces with the β-sheet region 
the DNA binding domain of RXRα (Figure 2.6-2). This β-sheet region is important for DNA 
binding, as shown by mutating Phe347 of the β-sheet S4 of PPARγ’s LBD into alanine, 
resulting in weakened ability to bind DNA (Chandra et al., 2008). However, rosiglitazone and 
BVT.13, latter interacting similar to amorfrutins away from helix H12 but involve helix H3 and 
the LBD’s β-sheet region, induce only minor variations of the overall conformation of the 
ternary complex (Chandra et al., 2008). Thus the effects of amorfrutin 1, 2, and B, as well as 
the effects of other related ligands on gene transcription are unlikely to be caused by 
structural changes affecting the DBD of RXRα and its DNA affinity. 
 
 
Figure 2.6-2: Overall structure of the PPARγ-RXRα complex on DNA (PDB 3DZY) according to 
Chandra et al. (2008). The expressed LBD of PPARγ for the experimental work in this study is drawn 
in blue, the PPARγ DBD in light blue, and RXRα in red. Co-activator peptides and rosiglitazone are 
drawn in black and yellow sticks, respectively. The three different interfaces are indicated by grey 
planes. The most important residues for amorfrutin interactions, Arg288 and Ser342, as well as the 
phosphorylation site at Ser245 and the residue Phe347, important for DNA interaction of the 
heterodimer, are labelled. 
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PPARγ contains a phosphorylation site at Ser245 (Ser273 in PPARγ2), residing between 
helix H2 and the β-sheet S1 (Choi et al., 2010), close to RXRα’s DBD. High fat feeding 
induces obesity in mice and activates the protein kinase Cdk5 (cyclin-dependant kinase 5) in 
adipose tissue, resulting in phosphorylation of this residue (Choi et al., 2010). The 
phosphorylation has no influence on DNA binding or general transcriptional activity, but alters 
the expression of a subset of genes with regulatory functions in metabolism, including a 
reduced transcription of the insulin-sensitising adipokine, adiponectin (Choi et al., 2010). 
Amorfrutin 1 and rosiglitazone were shown to block the phosphorylation of Ser245, which is 
apparently closely associated with their anti-diabetic effects (Choi et al., 2010) (Weidner et 
al., submitted). It is hypothesized that ligand-mediated interactions between helix H3 and the 
β-sheet ‘freezes’ this region in a conformation less favourable to Cdk5 phosphorylation (Choi 
et al., 2010). This leads to the suggestion of differentially regulated co-regulator recruitment 
in a phosphorylation-dependant manner (Choi et al., 2010) by a novel co-activator binding 
surface close to Ser245. Thus the inhibited phosphorylation by rosiglitazone or amorfrutin 1 
may initiate the recruitment of additional co-regulators, reasonable for dysregulated gene 
activation, like the enhanced transcription of the insulin-sensitising adiponectin, and the 
increased insulin sensitivity. Furthermore, regions outside the co-activators LXXLL motifs 
may also be involved and affect co-activator recognition and regulation (Klein et al., 2005). 
 
2.6.1.3 The active and inactive state of the PPARγ’s LBD 
The data demonstrate the unreliability of the inactive conformation even for the helix H12 
independant PPARγ activation. Crystallographic contacts to the loop linking H2’ and H3, 
called the omega-loop, lead to rotation and relocation of the amorfrutins in the cavity (section 
2.5.4). The omega-loop seems to be responsible for modulation of PPARγ activity by 
endogenous fatty acids like 15d-PGJ2 (Waku et al., 2009), illustrating the importance to 
distinguish between active and inactive form. Furthermore, crystallographic contacts to the 
omega-loop occlude parts of the ligand entry site and may thus exacerbate soakings of 
different ligands.  
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2.7 Outlook 
Due to the reported insulin-sensitising effects, the reduced fat storage and the improvement 
of metabolic and inflammatory parameters, which were ascribed to amorfrutin 1, it would be 
an exciting task to study the different effects of amorfrutin B, which exhibits a 12-fold higher 
binding affinity to PPARγ and to test if this compound exhibits improved, similar, or probably 
reduced effects. Especially the effect on the Cdk5 mediated phosphorylation of PPARγ’s 
LBD at Ser245 would be of special interest, as, to the current knowledge, it seems to be 
strongly associated with the anti-diabetic effect of substances like rosiglitazone, MRL-24, or 
amorfrutin 1. The higher binding affinity of amorfrutin B may contribute to a better 
stabilisation of the receptor and probably rigidify it in a higher degree as amorfrutin 1 or 
rosiglitazone do and hence may protect Ser245 more efficiently from Cdk5 mediated 
phosphorylation. It would be also possible that a structural related ligand with a higher 
binding affinity may reduce the dosing for the desired effect, which is currently with 10 
mg/kg/d amorfrutin 1 (Weidner et al., submitted) quite high. On the contrary, the more 
lipophilic structure and a possibly resulting reduced bioavailability in the organism may lead 
to reduced effects and a reduced insulin sensitising action. These effects remain elusive and 
have to be discovered in the future. 
Furthermore, as the PPARγ ligand 15d-PGJ2, a naturally occurring prostaglandin, was 
described to modify the receptors transcriptional activity by inducing structural changes to the 
omega-loop (Waku et al., 2009), residing between helix H2’ and H3, it would be also an 
exciting task to test if amorfrutins also induce a comparable and transcriptional relevant 
change to this region. As this region exhibits a high flexibility and thus was not visible in the 
present crystal structures, biophysical techniques appear to be more suitable to address this 
question. Method of choice may be the measurement of tryptophan fluorescence spectra of a 
K265W mutant of PPARγ (Waku et al., 2009). The mutation seems to be uncritical for ligand 
binding as K265 protrudes away from the LBD. The residue resides in the omega-loop and 
hence environmental changes around this area should become visible by changes of the 
spectra. Furthermore, the mutants I267A and F287A, residues of the omega-loop and helix 
H3, respectively, were described to dramatically decrease the receptors transcriptional 
activity in response to 15d-PGJ2, as these residues are responsible for the induced structural 
changes of the omega-loop without disturbing 15d-PGJ2 affinity (Waku et al., 2009). The 
amorfrutins interact close to the ligand entry side and the omega-loop and thus probably also 
affect the omega-loop conformation. Thus it would be of interest to analyse the amorfrutin 
mediated cell based transcriptional activity of these mutants in comparison to the wilde-type. 
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Additional mutants like R288T, R288A and R288H may be also of interest to quantify the 
contribution of the LBD’s Arg288 to amorfrutin binding, transcriptional activity, and to the 
selectivity of PPARγ to the amorfrutins in comparison to the other PPAR subtypes. R288T 
should mimic the residue of PPARα and PPARδ at this position and thus may give insights in 
PPARγ’s amorfrutin selectivity, compared with the wilde-type and the R288A mutant. The 
naturally occurring PPARγ mutant R288H is suggested to be associated with human 
colorectal cancer and was described to exhibit reduced affinity to naturally occurring ligands 
like 15d-PGJ2 or 9(S)-HODE (Section 2.6.1), shown to excessively interact with Arg288 
(Sarraf et al., 1999) (Section 2.6.1).   
However, one of the most important questions regarding PPARγ mediated transcriptional 
activation or dysregulation is addressed to probably additional co-regulator recruitment. The 
omega-loop region and the region around the phosphorylation site at Ser245 appear 
currently as the most suitable regions for such co-regulator recruitment. Thus it would be an 
exciting task to identify possible new co-regulators of PPARγ and discover new aspects of 
the mechanism of nuclear receptor regulation.  
Anyway, the insulin sensitising effect and the reduced fat storage upon ingestion of the non-
toxic amorfrutin 1 makes this naturally compound already very attractive for the possible 
usage as a drug to treat diseases like type II diabetes and/or obesity. Furthermore, as the 
amorfrutins are natural and non-toxic compounds, the usage of amorfrutins as dietary 
supplements to prevent type II diabetes and/or obesity may be also possible. Thus these 
compounds need to be tested by a human study to unveil possible human specific adverse 
effects and to give more detailed information about the metabolic action of these substances. 
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4 Accession Numbers 
Atomic coordinates have been deposited in the Protein Data Bank http://www.pdb.org with 
the PDB IDs given in Table 2.7-1. 
 
Table 2.7-1: Accession Numbers. 
Complex Title of the entry PDB ID 
IMDIRSp53:Tir Crystal structure of the I-BAR domain of 
IRSp53 (BAIAP2) in complex with an EHEC 
derived Tir peptide 
2YKT 
hPPARγ-LBD:amorfrutin_1  Ligand-binding domain of human PPAR 
gamma in complex with amorfrutin 1 
2YFE 
hPPARγ-LBD:amorfrutin_2 Ligand-binding domain of human PPAR 
gamma in complex with amorfrutin 2 
4A4V 
hPPARγ-LBD:amorfrutin_B Ligand-binding domain of human PPAR 
gamma in complex with amorfrutin B 
4A4W 
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